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1. INTRODUCTION 
 
1.1. Alzheimer’s disease 
Alzheimer’s disease (AD), first described in 1907 by Alois Alzheimer, is a 
neurodegenerative disorder [Alzheimer, 1907]. The term, AD was coined in 1910 by 
Kraepelin [Kraepelin, 1910], while the original research article was translated from 
German to English in 1995 by Stelzma and colleagues [Stelzma et al., 1995]. The disease is 
progressive and is characterized by cognitive defect [Glenner, 1982]. It begins at the 
hippocampus and progresses in a centrifugal manner, hierarchically from anterograde 
amnesia, speech impairment to loss of executive functions [Ray et al., 1998; Albert et al., 
2011; Arendt et al., 2017]. Generally, AD is categorized into two forms; the sporadic and 
the familial [Lendon et al., 1997; Ray et al., 1998; Bekris et al., 2010]. The familial AD 
which constitute about 5% of the disease shows Mendelian inheritance [Lendon et al., 
1997] while the sporadic AD which is influenced by environmental factors and/or genetic 
alteration account for about 95% of the disease [Bekris et al., 2010]. The disease can also 
be classified as early onset (30 – 60 years) or late onset (above 60 or 65), although old age 
is the major risk factor for the acquisition of AD [Bekris et al., 2010]. But, irrespective of 
which category or form (sporadic, familial, early onset or late onset) of the disease, AD is 
a dementing disorder and presents several symptoms [McKhann et al., 1984].  
Clinical symptoms of AD include but not limited to memory decline [Markowitsch; 
Staniloiu, 2012], loss of executive function and judgement [Stokholm et al., 2006], Apraxia 
[Parakh et al., 2004], olfactory dysfunction [Rahayel et al., 2012], sleep disturbances [Ju et 
al., 2014], and seizures [Hauser et al., 1986]. Other symptoms include; motor signs defect 
[Portet et al., 2009], atypical presentation [Galton et al., 2000; Alladi et al., 2007] and 
mixed dementias [Galasko et al., 1994]. As disease advances, hypertonia, incontinence, 
mutism and myoclonus, pneumonia, malnutrition arises. And it is these complication 
(such as pneumonia, malnutrition, recurrent infection) that result in the death of an AD 
person and not the dementia which is the symptom of the disease [McKhann et al., 1984; 
Ray et al., 1998; Bekris et al., 2010].  Alzheimer’s disease is characterised by two major 
histological hallmarks; neurofibrillary tangles (NFT) and neuritic plaques [KIDD, 1963; 
KIDD, 1964; Glenner; Wong, 1984; Glenner; Wong, 1986; Brion, 1998].  
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1.1.1. The neuritic plaque 
The neuritic plaques are insoluble extracellularly deposits consisting of several proteins 
such as amyloid precursor protein (APP), apolipoprotein E, α1- antichymotrypsin, IgG, 
several complements protein and glycosaminoglycans [Namba et al., 1991; Ghiso et al., 
1993; Strittmatter; Roses, 1996]. However, of all the protein constituents, amyloid beta 
(Aβ), a proteolytic cleavage (39 - 43 amino acid long) derived from amyloid precursor 
protein is the major component of neuritic plaque [Ghiso et al., 1993; Ray et al., 1998]. 
The APP belongs to the type I membrane protein family and is found in a variety cells but 
particularly in brain cells [Zheng; Koo, 2011; Coronel et al., 2018]. The actual biological 
function of this protein is unclear, but it has been suggested to function in neural growth, 
maturation, synaptogenesis and axonal outgrowth after injury [Wang et al., 2014; Coronel 
et al., 2018]. In the brain, APP is produced in the astrocytes and neurons [Puig; Combs, 
2013; Brothers et al., 2018]. Typically, APP is constitutively cleaved by alpha (α), beta (β) 
and gamma (γ) secretases to produce soluble fragments such as secreted APPα (sAPPα or 
sAPPβ), Aβ peptides (including Aβ1-40, Aβ1-42, or Aβ1-43), and 3-kDa peptide (P
3) respectively 
[Chow et al., 2010; Nhan et al., 2015]. However, due an unclear mechanism in the brain, 
Aβ monomers self-assemble [Tycko, 2016] to aggregate and form oligomers [Brothers et 
al., 2018]. Further aggregation of the peptides progresses to oligomers, protofibrils and 
finally fibrils. Other cellular components subsequently combine with the aggregated fibril 
and then form insoluble deposit called Aβ plaque (amyloid plaque). Since APP is a 
membrane protein, the generated insoluble Aβ fragments becomes extracellular deposits. 
The commonly produced monomeric peptides of amyloid protein in this pathology are 
the Aβ40 and Aβ42 [Thinakaran; Koo, 2008; Grimm et al., 2013; Dawkins; Small, 2014; 
Coronel et al., 2018]   
 
1.1.2. The neurofibrillary tangles 
Neurofibrillary tangles on the other hand are intracellular deposits consisting mainly of a 
microtubule associated protein, tubulin the associated unit (tau) within dystrophic 
neurons [Strittmatter; Roses, 1996; Ray et al., 1998]. The tau protein belongs to the 
family, microtubule associated proteins (MAPs) and it was discovered in the year 1975 
[Weingarten et al., 1975; BERKELEY, 2009]. In human central nervous system (CNS), tau 
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gene is located on the long arm of chromosome 17q21 [Neve et al., 1986] and alternative 
splicing of the tau transcript gives rise to six (6) isoforms in the CNS [Goedert et al., 1989]. 
Natively, the protein is unfolded, flexible, mobile [Guo; Lee, 2011] and consists of four (4) 
regions; N terminal (1 to 150 amino acid), proline rich (151 to 243 amino acid region), the 
microtubule binding region (MTBR) and the C-terminal (370 to 441 amino acid 
region)[Guo et al., 2017]. In adult human brain, the MTBR on a single isoform of tau exist 
in either 3 or 4 repeats (3R or 4R) with a 50:50 ratio.  
Tau protein uses its MTBR region to bind microtubules and stabilize them [Spires-Jones et 
al., 2009]. The binding affinity between the MTBR of the tau and the microtubules is 
regulated by several post-translational modifications (such as nitration, phosphorylation, 
glycosylation, proteolysis and glycation), however, phosphorylation is the primary 
mechanism controlling this binding process [Morris et al., 2015]. The tau protein has 
about 85 potential phosphorylation sites [Buerger et al., 2002; Hansson et al., 2006; 
Goossens et al., 2017] and the ability for the protein to become phosphorylated is tightly 
regulated by the balance between kinases (such as glycogen synthase kinase 3β and cyclin 
dependent kinase 5) and phosphatases (such as protein phosphatase 2A) activities 
[Mazanetz; Fischer, 2007].  
 
1.1.3. Pathophysiology of NFT 
Due to an unclear mechanism in pathological state, kinases activity becomes upregulated 
while phosphatases become downregulated leading to abnormal phosphorylation 
(hyperphosphorylation) of the tau protein [Kolarova et al., 2012]. And as tau protein 
becomes hyperphosphorylated its binding affinity for microtubules becomes very weak 
and it therefore detaches [Lindwall; Cole, 1984; Bramblett et al., 1993]. Once tau protein 
dissociates from the microtubules it relocates into the somatodendritic region of the cell. 
At the somatodendritic compartment, tau protein undergoes further modification such as 
phosphorylation which subsequently aggregate to form tau filaments [Spires-Jones et al., 
2009] or sequester other neuronal microtubules associated proteins, MAP1 and MAP2 
[Alonso et al., 1997]. Further aggregation of the fibril develops into tangles 
(neurofibrillary tangles) which become toxic species to the cell leading to its death and 
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loses, a phenomenon that characterised AD. And as the tau protein is intracellularly 
located, the tangle that form is also intracellularly deposited [Spires-Jones et al., 2009] 
Again, tau protein, which is primarily found in the axons of neurons, functions as a glue to 
hold and stabilize the microtubules thereby bridging the cytoskeletal connection [Goedert 
et al., 1989; Gu et al., 1996; Brion, 1998; Guzmán-Martinez et al., 2013]. This key function 
of tau protein is necessary to maintain the normal morphology (such as growth) and the 
biological role (such as intracellular transport) of neuronal cell [Weingarten et al., 1975; 
Grundke-Iqbal et al., 1986; Mandelkow; Mandelkow, 2012]. But, when the tau protein 
dissociates from the microtubules, it destabilizes bridging connectivity within the 
cytoskeleton and potentially collapse the axonal region leading to obstruction of 
information flow within the neuron [Masliah; Terry, 1993]. Following this obstruction of 
communication dynamics and axonal transport within the cell, neuronal cell death and 
loses which is generally term, neurodegeneration arise [Terry et al., 1981; Kolarova et al., 
2012] 
Neuronal death has a rippling effect on the neighbouring cells because the aggregated 
deposit from the dead cells obstruct synaptic transmission to healthy neurons and 
subsequently lead to synaptic loses [Hof et al., 1990; Masliah; Terry, 1993].  And as intact 
synapses are a fundamental requirement for the physiological functioning of the neurons, 
a quantitative decrease in these structures (synapses) affect the neurons and result in 
massive pathological changes in the brain [Hof et al., 1990; Masliah et al., 1991]. An 
extensive review of tau protein in neurodegeneration is provided elsewhere [Buée et al., 
2000; Avila et al., 2004; Spires-Jones et al., 2009; Kolarova et al., 2012; Arendt et al., 
2016; Pîrşcoveanu et al., 2017]. 
 
1.2. Epidemiology and socio-economic burden of Alzheimer’s disease  
In 1990, about 20.2 million people had dementia, however, this number increased to 43.3 
million in 2015 with women recording the highest number [Nichols et al., 2019]. In 2016, 
27.0 million women and 16.8 million men had dementia and currently dementia linked 
associated complication is the fifth leading cause of death, accounting 2.4 million death 
[Nichols et al., 2019]. And of these numbers, AD constitutes between 60% - 80% of all the 
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cases [Alzheimer’s Association, 2019]. More so, a projection of approximately 131 million 
people are likely to suffer from the disease by 2050 worldwide [Homolak et al., 2018], a 
figure that is alarming.  
The prognostic outcome after administering AD drugs (such as donepezil, galantamine, 
rivastigmine, memantine, neuronal IGF-1 or Docosahexaenoic acid) to individuals 
diagnosed of AD has resulted in unsatisfactory outcome [Tariot et al., 2009; Homolak et 
al., 2018], possibly because the disease is diagnosed at its advanced stage [Hogervorst et 
al., 2003]. Each year over 5 million cases of AD are reported globally [Bekris et al., 2010]. 
And until pragmatic efforts are made towards prevention, early diagnosis or treatment of 
the disease, AD will constitute an increasing heath care challenge globally. As of 2015 the 
care of about 35 million persons living with AD and other dementia was estimated to be 
around $600 billion [Marešová et al., 2015]. Besides, AD patients stay in hospital beds 
twice longer in a year than older person, and this affect other emergency service [Hurd et 
al., 2013].   
Alzheimer’s disease faces two major challenges; definite factors that trigger the disease 
which is unknown, and a lack of affordable diagnostic platform for early detection of the 
disease. This is particularly important because molecular and cellular aberrations occur 
long (almost 20 years) before the onset of detectable clinical symptoms [Lendon et al., 
1997]. 
 
1.3. Clinical diagnosis of Alzheimer’s disease 
The guideline for the diagnosis of AD was established 35 years ago [McKhann et al., 1984] 
however, this criterion has gone through series of revisions over the past years. Currently, 
the predictive diagnostic criteria for AD is based on neuropsychological evaluation test, 
neuroimaging and biochemical measures of cerebrospinal fluid (CSF) protein markers 
[McKhann et al., 2011; Arevalo-Rodriguez et al., 2015]. 
The neuropsychological test commonly employed include the Mini-Mental State 
Examination (MMSE) [Folstein et al., 1975] Montreal Cognitive Assessment (MoCA) 
[Nasreddine et al., 2005], Saint Louis University Mental Status (SLUMS) [Tariq et al., 2006] 
and Consortium to Establish Registry for Alzheimer’s disease (CERAD) [Morris et al., 
1989].  
Magnetic resonance imaging (MRI), computed tomography (CT), 18fluorodeoxyglucose 
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positron emission tomography (18fPET), single-photon emission computed tomography 
(SPECT), Aβ positron emission tomography (Aβ-PET) and diffusion tensor imaging (DTI) 
are among the commonly used neuroimaging technique for the diagnosis of AD [Ferreira; 
Busatto, 2011]. The MRI visualizes general brain atrophy in the medial temporal lobe and 
white matter lesions [Whitwell et al., 2012], the CT identifies gross abnormality of the 
brain, and the DTI demonstrate loss of white matter integrity in the limbic and cortico-
cortical tracts [Ferreira; Busatto, 2011]. Amyloid beta deposition in the brain can be 
identified by Aβ-PET [Rabinovici; Jagust, 2009], while possible regional brain 
hypoperfusion and hypometabolism can be demonstrated by SPECT and 18fPET 
respectively [Cummings, 2012]. In recent times, the advent of tau-specific tracers for use 
with PET has enabled in vivo quantification of NFT, particularly tau deposition in the 
brain, and this diagnostic pathway is currently under clinical validation [Saint-Aubert et 
al., 2017; Okamura et al., 2018; Leuzy et al., 2019]. However, of all the neuroimaging 
techniques, Aβ-PET is the gold standard method for diagnosing AD [Morris et al., 2016].  
 
The biochemical measurement of β-amyloid, total tau and phosphorylated tau proteins in 
the CSF are the current fluid-based diagnostic method for AD in clinical use [McKhann et 
al., 2011].  The rationale behind the measurement of CSF β-amyloid (either Aβ40 or Aβ42) 
stems from the fact that, in AD there is an aggregation and sequestration of amyloid 
protein to forming cerebral plaque. And because of this aggregation and accumulation of 
the amyloid in the brain, the CSF becomes deficient of the protein and hence less 
accessible for measurement [Pawlowski et al., 2017]. On the contrary, an increase in CSF 
tau protein concentration is an indication for positive predictive diagnosis for AD. This 
follows the assumption that, in AD, neurons rapidly expel the intracellularly accumulated 
toxic tau protein into CSF to relief the cell of stress and neuronal death. And this increases 
the tau protein content in the fluid. Hence, the CSF tau protein levels are directly 
proportional to the intensity of neuronal damage in the brain [Blennow et al., 2012; 
Pawlowski et al., 2017]. Altogether, an increase in CSF tau and decrease in β-amyloid 
protein level is considered as one of the useful indications for predicting probable AD.  
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1.4. Challenges associated with the current diagnosis of AD 
Despite the diagnostic value of the neuropsychological testing, neuroimaging or CSF 
biomarkers, definite diagnosis of AD requires histopathologic examination which can be 
performed at post-mortem and this does not benefit the patient. In addition to the fact 
that the available antemortem diagnostic methods only identify the disease in its 
advanced stage, the methods are challenged by several factors [Hogervorst et al., 2003; 
Nagasaka et al., 2005; Khan; Alkon, 2015]. For instance, the neuropsychological test which 
can be performed without sophisticated equipment is influenced by a person’s education 
and race [Crum et al., 1993]. The neuroimaging techniques which can provide both 
qualitative (standardized) and quantitative evaluation of AD diagnostic markers is not 
only expensive but there are issues regarding what constitutes a positive test and the 
interpretation of positive result [Yang et al., 2012].  
Again, the biochemical assay of CSF biomarkers which provide quantitative information 
on possible AD patients is characterised by some drawback. For instance, circadian 
rhythm as well as old age phenomenon (or old age-associated diseases) are potential 
factors that can influence the levels of CSF markers [Kang et al., 2009; Homolak et al., 
2018]. Also, the predictive value of increased CSF tau level and deceased Aβ1-42 for AD 
diagnosis is insufficient. This is because a decreased CSF tau and increased Aβ1-42 has also 
been observed in control subjects [Motter et al., 1995; Gasparini et al., 1998] and raises 
further concern about the sensitivity and specificity of this diagnostic tools. Besides, the 
CSF markers are also involved in secondary inflammation [Akingbade et al., 2018], 
sampling for CSF involves lumber puncture, an invasive and uncomfortable technique. 
To overcome these challenges associated with AD diagnosis, there is the need to explore 
other potential sources for AD biomarkers that can unambiguously predict the disease 
antemortem. Characteristically, such an ideal clinical biomarker should be indicative of 
damage, detect the disease before the onset of histopathological alteration and must be 
sensitive. Besides, such a marker should correlate significantly with the severity of 
damage, be analytically stable and measurable in the peripheral tissue such as blood and 
produce same result irrespective of the species. Fundamentally, such a possible 
diagnostic marker should have a known mechanism and able to localize damage 
[Robinson et al., 2008]. Several AD-linked biomarkers have been evaluated in peripheral 
tissue. These includes: the Aβ peptides (Aβ1–40, Aβ1–42), Tau proteins (total tau, p-tau-
 8 
 
181), Inflammatory proteins (C-reactive protein, antichymotrypsin, macroglobulin, 
interleukins, tumour necrosis factor, complement factors, homocysteine), metabolism 
(lipidomics & proteomics) and other (Clusterin, APOE) [Khan; Alkon, 2015]. The outcome 
has been interesting; for instance, although a decrease in β-amyloid has been observed in 
the blood of AD patients, subsequent studies were inconsistent [Irizarry, 2004; Khan; 
Alkon, 2015]. Similarly, a dysregulation in the signaling pathways as well as differences in 
the distribution of leucocytes has been observed in the blood of AD and mild cognitive 
impaired patients [Wyss-Coray, 2006; Ray et al., 2007; Khan; Alkon, 2015]. 
 
Recently, extracellular vesicles (ECVs) have come in focus in the field of biomarker 
research. Thus, ECVs have been found to be an important source of diagnostic biomarkers 
for cancers [Tai et al., 2018], human immunodeficiency virus disease [Patters; Kumar, 
2018]. Similarly, there are growing concerns about the potential role of these ECVs in the 
diagnosis of AD. 
 
1.5. Extracellular vesicles 
Extracellular vesicles (ECVs) are heterogeneous, lipid bilayer membrane-bound carriers 
[Maas et al., 2017]. Although these vesicles are referred to by several names such as 
exosomes, microvesicles (ectosomes), microparticles and oncosomes [Maas et al., 2017], 
they are broadly categorized as exosomes and microvesicles [van Niel et al., 2018]. The 
exosomes which are the smallest in terms of diameter, were discovered in 1983 by Pan 
and Johnstone in one research group [Pan; Johnstone, 1983], and Harding and Stahl in 
another research group [Harding; Stahl, 1983]. Microvesicles were also described by Tram 
and colleagues somewhere in the 20th century [Trams et al., 1981]. However, until now a 
major controversy exists regarding the definite distinction between exosomes and 
microvesicles [Słomka et al., 2018]. An extensive review of extracellular vesicles is 
available elsewhere [van Niel et al., 2018; Słomka et al., 2018]. Mindful of the 
considerable overlap between exosomes and microvesicles [Lai; Breakefield, 2012; 
Raposo; Stoorvogel, 2013], the term ECVs is adopted in this current research for clarity. 
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1.5.1. Formation of ECVs (ectosomes and exosomes) 
Microvesicles (ectosomes) are formed by the outward budding of the plasma membrane 
into extracellular milieu [Lai; Breakefield, 2012]. On the contrary, the formation the 
smallest ECVs (the exosomes) are via a more complex pathway. The formation of 
exosomes starts when a receptor on the plasma membrane is internalized (invaginated) 
to form early endosome containing ubiquitinated cargo. In the cell, endosomal sorting 
complex required for transport (ESCRT) facilitate the maturation of the early endosome 
into late endosomes [Lai; Breakefield, 2012; Colombo et al., 2014]. Further inward 
budding of the late endosome results in a progressive accumulation of intraluminal 
vesicles to form a multivesicular body. 
Following a regulation mechanism control by ESCRT, a multivesicular body has two fates; 
either it gets phagocytosed by lysosomes or exits the cell via the exocytic pathway 
[Colombo et al., 2014]. Possibly due to the composition of the intraluminal vesicles, a 
multivesicular body destiny for exocytic pathways is further regulated by both dependent 
and the independent (involving tetraspanins) activities of ESCRT [; Kanninen et al., 2016; 
Vogel et al., 2018]. But whichever pathway (dependent or independent of ESCRT) a 
multivesicular body adopts, it ultimately fuses with the plasma membrane (exocytic 
multivesicular body) and release its contents (intraluminal vesicles containing cargos) into 
the extracellular space as ECVs. And, since different pathways of ESCRT (such as the 
dependent and independent) are involved in the biogenesis of multivesicular bodies, a 
given cell may release several subpopulations of ECVs having varied composition 
[Bebelman et al., 2018]. The ECVs are found in several biological fluids such as blood, 
semen, urine, breast milk, ascites, cerebrospinal fluid, malignant pleural effusions, 
amniotic fluid, tears, saliva, mucus, lymph, and bronchial lavage [Simpson et al., 2008; 
Lakhal; Wood, 2011; Ibrahim; Marbán, 2016].  
 
1.5.2. Size, density and composition of ECVs 
Extracellular vesicles are characterized based on their size (diameter), density and 
composition [Kanninen et al., 2016]. The smallest category of ECVs is known to have a size 
range 30nm to 150nm [Théry et al., 2002; Muller et al., 2014; Zeringer et al., 2015; 
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Matsumoto et al., 2017], while the larger ones are between 100nm to 1000nm [Raposo; 
Stoorvogel, 2013; Słomka et al., 2018]. Typically, ECVs float at a buoyant density ranging 
from 1.08 to 1.22g/ml [Tauro et al., 2012; Muller et al., 2014; Colombo et al., 2014; Kalani 
et al., 2014; Pérez-González et al., 2017]. Based on their composition, ECVs contain 
several marker proteins which are either located on the surface or lumen of the vesicles. 
These markers include; tetraspanin proteins (CD9, CD63, CD81 and CD82), the heat shock 
protein (HSP70 and HSP90), the membrane trafficking protein (Rabs and Annexins). 
Others are; the proteins involve in multivesicular bodies biogenesis, the immune 
regulator molecules, the cytoskeletal, signal transduction proteins and metabolic 
enzymes [Frühbeis et al., 2012; Colombo et al., 2014; Jakobsen et al., 2015; Sastre et al., 
2017; Li et al., 2017]. Most cells can release ECVs which contain repertoire of signatories 
from the parental cells [Kanninen et al., 2016] 
Although several cells such as neural stem cell, neurons, oligodendrocytes, astrocytes and 
microglia cells can release ECVs, these cell-specific vesicles are distinguishable [Ghidoni et 
al., 2011; Lachenal et al., 2011; Vogel et al., 2018]. This is possible because cell specific 
ECVs contain unique marker proteins in addition to the general marker proteins that 
characterised the vesicles [Simons; Raposo, 2009]. For instance, ECVs release by neurons 
are uniquely characterized glycosylphosphotidylinositol anchored prion protein, GluR2/3 
subunit of the AMPA receptor and Cell adhesion molecules L1/ CD171 [Fauré et al., 2006; 
Maness; Schachner, 2007; Chivet et al., 2012; Mustapic et al., 2017; Yoo et al., 2018]. 
Microglial cells’ ECVs contain CD13 and monocarboxylate transporter, while, 
oligodendrocytes ECVs contain myelin proteins and associated lipids [Kanninen et al., 
2016]. Therefore, the presence of these cell-specific markers has been helpful for the 
identification ECVs subpopulations.  
 
1.5.3. Functions of central nervous system ECVs 
Functionally, ECVs released from the CNS may dispose unwanted cellular materials or 
provide signalling information to other cells. The signalling information carried by ECVs 
may include proteins, RNA and lipids which can modulate the state of the recipient cell 
[Frühbeis et al., 2012]. Although ECV has emerged as a third (beside direct cell-cell 
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contact and transfer of secretory molecules) way for intercellular communication 
[Simons; Raposo, 2009], the role of these vesicles in the CNS is attracting major attention. 
For instance, astrocyte derived ECVs carries synapsin1, a protein capable of facilitating 
the survival of neurons during oxidative stress [Frühbeis et al., 2012]. Similarly, the cargo 
(miRNA) of neuronal derived ECVs can also activate the functions of glial cells which 
subsequently contribute to the clearing of Aβ deposition in the brain [Soria et al., 2017]. 
And, both neurons and microglia can take-up oligodendrocytes derived ECVs to mediate 
neuroprotection [Kanninen et al., 2016]. Neurons can internalize glia ECVs, utilize its 
content and subsequently releases more neuron ECVs [Frühbeis et al., 2012]. Therefore, 
Glia and neuron ECVs have been suggested to be responsible for inter-neuronal transfer 
of physiological information within the brain circuit [Chivet et al., 2012]. Non-coding 
RNAs, miRNAs, RNAs, lipids and proteins are among the major constituent molecules of 
ECVs [Lai; Breakefield, 2012; Kalani et al., 2014]. Therefore, the phenotypic state of these 
cargo molecules may mirror the nature of their originating cell [Kalluri, 2016]. ECVs have 
been proposed to represent a novel mode of intracellular communication which could 
lead to immunological responses and other cellular processes [Zhang et al., 2017]. For 
instance, ECVs secreted by B lymphocytes have the capacity to act as a vehicle to shuttle 
‘major histocompatibility complex’ class II peptide between cells [Colombo et al., 2014].  
Although ECVs have been suggested to participate in functional cellular processes, they 
have also been implicated in several pathological states including trans-synaptic 
transmission of pathogenic proteins [Lachenal et al., 2011]. The possible role of ECVs in 
pathological conditions is gaining concerns. Thus, it is emerging that ECVs can parade as 
vectors and facilitates the exchange of pathological proteins [Fauré et al., 2006]. The 
presence of tau protein inside ECVs [Polanco et al., 2016] and the ability of this vesicle to 
cross the blood brain barrier [Süssmuth et al., 2001; Lakhal; Wood, 2011] raises further 
suspicion about the potential role of ECVs in the propagation of PHF in AD.  
 
1.6. Tau protein, ECVs and peripheral blood 
As the protein loses it functional properties and detaches from the microtubules in the 
axons it relocates into the neuronal cytoplasm. But because this abnormally modified tau 
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is toxic to the neurons [Alonso et al., 1997], the cell may expel this lethal protein in an 
enclose structure such as ECVs. This is possible because, the mechanism by which ECVs 
transfer functional proteins among neurons is suggested for how pathologic tau protein 
are also shuttled [Bartheld; Altick, 2011]. Thus, neurons release pathologic tau proteins 
into the extracellular space by activity dependent fashion to be taken up by other neuron 
[Bodea et al., 2016], a mechanism that can equally be employed by ECVs. Since ECVs and 
tau protein enter recipient neurons by endocytosis [Lu et al., 2007; Frühbeis et al., 2012; 
Michel et al., 2014] via ECVs mediated mechanism [Saman et al., 2012], the two (ECV and 
tau) may be closely linked. Hence, ECVs may provide as a vehicle that transport tau 
protein [Saman et al., 2012].  
Previous studies have demonstrated that AD-like tau proteins are present in peripheral 
blood [Fiandaca et al., 2015; Abner et al., 2016; Winston et al., 2016; Guix et al., 2018]. 
But, since free floating tau proteins are susceptible to proteolytic degradation by 
thrombin [Arai et al., 2005], it is practical to suggest that, the protein is transported in an 
enwrapped medium. Enwrapping of tau protein may be an important process to shield it 
from truncation or degradation by thrombin. This is particularly important as tau can 
cross the blood brain barrier (BBB) [Lakhal; Wood, 2011], transverse cerebrospinal fluid 
into peripheral circulation [Weinstein; Seshadri, 2014], or shuttle among neuron, a 
process that an unwrapped protein may not survive it.  
And as the formation and release of ECVs are ubiquitous and cell type-specific, neuron 
derived extracellular vesicles (ndECVs) may be the specific vesicles that transport this 
abnormal tau protein. Particularly, as it is known that ndECVs can cross the BBB into CSF 
[Süssmuth et al., 2001; Lakhal; Wood, 2011; Kanninen et al., 2016] and subsequently into 
the peripheral blood circulation [Weinstein; Seshadri, 2014]. 
Beside the fact that ndECVs contain signatories of their parental cell, such vesicles may 
also harbour useful information that reflects the state of the originating cells. Therefore, 
this study hypothesized that blood-based ndECVs could represent a reliable source for AD 
diagnostic marker, tau protein and further provide as a surrogative source for quantifying 
AD-linked tau protein using flow cytometry technique.  
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1.7. Aim of the study 
The detection and quantification of tau protein in blood-based ndECVs has been reported 
[Guix et al., 2018], however, the significance of this proteins in the ECVs for diagnosis of 
AD remain largely unclear. Hence, this study aimed to quantify tau protein in blood-based 
ndECVs using flow cytometry technique and evaluate the significance of the measured 
proteins in the diagnosis of AD. 
Flow cytometry is a reliable, simple and a sensitive analytical technique that uses light to 
either qualitatively or quantitatively profile biological particles such as cells or vesicles in 
suspension. Flow cytometry technique has been employed in several studies that were 
aimed to quantify biological molecules such as DNA [Hedley et al., 1983], apoptosis 
[Riccardi; Nicoletti, 2006], cell cycle [Pozarowski; Darzynkiewicz, 2004], haematopoietic 
cells [Lanier; Warner, 1981], and therefore it is appropriate to adopt the technique in this 
current study.  
 
1.8. Objectives 
As blood contains a mixture of ECVs from several cells, a research aimed at a cell type-
specific vesicle should first concentrate, isolate, purify, characterize and verify the vesicles 
before quantifying the cargo proteins content in the vesicles. Therefore, this study set the 
following objectives:  
(i) Establish a protocol for the isolation and characterization of ECVs and ndECVs 
using western blot and flow cytometry technique  
(ii) Use the flow cytometry platform to quantify tau protein in the blood-based 
ndECVs of clinical patients who had already undergone the routine clinical diagnostic 
procedures (such as CSF tau, CSF p-tau, CSF β-amyloid or MMSE evaluation),  
(iii) Evaluate the significance of tau protein in the ndECVs as a potential biomarker for 
AD. 
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2. METHODOLOGY  
 
2.1. Study design 
This study employed both retrospective and prospective cross-sectional design and was 
performed from 2016 to 2019 at Paul Flechsig institute of brain research (PFI), Universität 
Leipzig, Leipzig, Germany. Blood samples from humans as well as Mesocricetus auratus, 
and cell cultured supernatant from human neuroblastoma cell line SH-SY5Y that has been 
transfected with cDNA for human tau protein were used.  
 
2.2. Ethical issues 
This study was approved by Leipzig research ethical committee and had a reference 
number, 329/16-ek. Participants’ identity remained anonymous to this study and only 
arbitrary numbers were assigned to the samples. Blood samples from Mesocricetus 
auratus (TVV 17/13) were provided by PD Dr.rer.nat. Max Holzer of Paul Flechsig Institute 
of Brain Research (PFI), Universität Leipzig, Leipzig, Germany. Human blood samples were 
obtained from colleagues at Paul Flechsig Institute of Brain Research and patients from 
Klinik für Psychiatrie der Universität Leipzig. 
 
2.3. Materials 
Table 1: List of biological samples used 
Samples type Total 
number 
source purpose 
Human (healthy young adult) 9 PFI protocol establishment 
Human (patient samples) 28 clinic quantification of tau protein 
Mesocricetus auratus 20 PFI Positive control 
SH-SY5Y cell N/A PFI Positive control 
Neuro-2A cells N/A PFI Negative control (WB) 
PFI - Paul Flechsig institute of brain research, WB - western blot, N/A – not applicable 
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Table 2: List of antibodies used for western blot analysis 
Antibody (primary)  CatLog 
number 
company Dilution country 
Monoclonal mouse 
HSP70 
L1813 Santa Cruz 
Biotechnology 
1:2000 Germany 
Polyclonal goat anti 
CD63 
AB0047-200 SICGEN 1:3000 Germany 
Polyclonal rabbit anti-
CD9 
L1214 Santa Cruz 
Biotechnology 
1:3000 Germany 
Polyclonal rabbit anti-
human tau 
A0024 Dako 1:4000 Germany 
Antibody (secondary)     
Polyclonal rabbit anti-
Mouse 
immunoglobulins 
HRP 
P0260 Dako 1:10,000 Germany 
Polyclonal rabbit anti-
goat immunoglobulin 
HRP 
P0449 Dako 1:10,000 Germany 
Polyclonal goat anti-
rabbit 
immunoglobins HRP 
P0448 Dako 1:10,000 Germany 
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Table 3: List of antibodies used for flow cytometry  
Antibody (primary)  CatLog 
number 
company Dilution 
with bead 
 ECVs 
volume 
Mouse monoclonal 
anti-human 
CD171Biotin 
Clone 5G3 eBiosciences 1:5 50µl 
Mouse monoclonal 
anti-human CD9 
(HBM-CD9-20) 
140815 HansaBioMed Life 
sciences 
1:200 100µl 
Mouse monoclonal 
anti-CD63Biotin clone 
H5C6 
B191782 BioLegend 1:5 5µl 
ALEXA Fluor 488 
(HBM-A488) 
070915 HansaBioMed  
Life sciences 
1:1000 N/A 
Mouse monoclonal PE 
anti CD9 (clone HI9a) 
312105 BioLegend 1:10 N/A 
N/A – not applicable 
 
Table 4: List of equipment including consumables 
Equipment CatLog number/ID company country 
Abbe-refractometer Modell G Jena Germany 
AmershamTM HydondTM 
PO.45 (PVDF) 
10600023 GE Health Life 
Sciences 
Germany 
Blood test tube  
(S-monovette® 7.5ml) 
7030411 SARSTEDT Germany 
Dnr Bio-Imaging System MF-chemiBis 1.6 Biostep® GmbH Germany 
Eppendorf tube  Eppendorf Germany 
ELISA plate washer hydrospeed Tecan Germany 
Greiner bio-one 650180 CELLSTAR Germany 
 18 
 
Table 4 (continuation): List of equipment including consumables 
Equipment CatLog number/ID company country 
Guava easyCyteTM  M Millipore USA 
Heraeus multifuge X1R rotor 75003658 Thermo Fisher 
Scientific 
Germany 
Electro-blotter 20 X 
20cm (TV 400-EBK) 
300017547 Biostep GmbH Germany 
Master cycler gradient  Eppendorf Germany 
Micro-ultracentrifuge 
(SORVALL MTX 150) 
Rotor S52-ST, 2045 Thermo Fisher 
Scientific 
Germany 
Multichannel 
Finnpipette 
C93910 Labsystems Germany 
PCR tubes (0.2ml) G006-TUCA Kisker Biotech Germany 
SIGMA laboratory 
centrifuge (3K30) 
rotor 12154-H  Thermo Fisher 
Scientific 
Germany 
Rotating roller 
(RM5.40) 
705977 Assistant Germany 
SETON open-top 
centrifuge tube (13 x 
51mm) 
32516 polyclearTM USA 
SORVALL® COMBI PLUS AH 629 Thermo Fisher 
Scientific 
Germany 
96 well Greiner plate E14011AY (655061) Greiner Germany 
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Table 5: List of reagents 
Reagent CatLog number company Country 
Acrylamide/Bis 37:7:1 10688.01 SERVA Germany 
Aldehyde/Sulfate Latex bead 
(4% w/v, 4µm) – 1.5µl 
A37304 Thermo Fisher 
Scientific 
Germany 
Ammonium persulfate 9592.2 ROTH Germany 
Cyto-lastTM buffer B181625 Miltenyi Biotec Germany 
Dulbecco’s Modified Eagles 
Medium 
0685G,FG4815 Dulbecco Germany 
EXO-Prep HBM-EXP-B5 Hansa BioMed 
Life Sciences 
Estonia 
exosome standard 06032 Hansa BioMed 
Life Sciences 
Estonia 
Fetal calf serum  BS255756 BIO & SELL Germany 
Glycine 3908.3 ROTH Germany 
Greiner bio-one (10cm dish) E130702L CellStar® Germany 
Gentamycin 50mg/ml 
(1000x)  
BS. 
AB17.03.03100 
BIO & SELL Germany 
HBM-SB sample buffer 091015 HansaBioMed 
Life Sciences 
Estonia 
Inside Fix 5140807265 Miltenyi Biotec Germany 
Inside Perm 5140807265 Miltenyi Biotec Germany 
JetPEI (polyethylenimine) 614201 Polysciences Germany 
Lumigen ECL utra solution A 
and B 
TMA-100 Lumigen USA 
non-essential amino acid K0293 M Biochrome 
GmbH, 
Germany 
Opti-MEM® 11058-021 gibco UK 
Protease inhibitor (2% 
cOmplete™ EDTA free) 
4693132001 Roche Germany 
Sodium hydroxide (NaOH) 502790987 Praha 
Chemapol 
Czechoslovakia 
Streptavidin MagneSphereR   
(1µm) – 5µl 
Z5481 Promega Germany 
Tetramethylethylenediamine 2367.1 ROTH Germany 
Tris 4855.5 ROTH Germany 
Tween® 20 327259797 ROTH Germany 
BSA/ Albumin bovin Fraction 
V 
170146 SERVA Germany 
VISIPAQUETM 320 10328257 Amersham Germany 
triton x-100 37240 SERVA Germany 
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Table 6: List of prepared consumables 
10% SDS-PAG 
Separating gel 
Distilled water – 4.88ml 
1.5M tris-HCL, pH 8.8 – 3.0ml 
Acrylamide/Bis solution –4ml  
10% SDS – 120µl 
10%APS – 100µl  
TEMED – 10µl 
 
Stacking gel 
Distilled water – 4.41ml 
1.0M tris-HCL, pH 6.8 – 0.75ml 
Acrylamid SL – 0.78ml  
10% SDS – 60µl 
10%APS – 60µl  
TEMED – 6µl 
 
SDS running buffer 
Tris base – 30.3g 
Glycine – 144.4g 
SDS – 10g 
1L of ddH2O 
 
TBS  
50mM Tris 
150mM NaCl 
DdH20 
 
B/S-N blot buffer 
(10x, 1litre) 
48mM Tris 
38mM glycin 
distilled water 
 
10ml 4X SDS sample 
loading buffer 
2ml 1M TRIS HCl PH 6.8 
0.8g SDS 
4ml Glycerol 
400µl of 14.7M β-
mercaptoethanol 
8mg bromophenol blue 
 
1% BSA sample buffer 
BSA – 1g 
PBS – 100ml 
 
 
 
Table 7: List of antibodies used for enzyme linked immunosorbent assay (ELISA) 
Antibody CatLog 
number 
company Final 
concentration 
ECVs 
volume 
Anti tau antibody clone 1G2 
(non-phospho-epitope) 
0714-02 AJ Roboscreen 4µg/ul 25µl 
Anti-human tau antibody 
clone 7E5 
07/17-02 AJ Roboscreen 0.16µl/ml 
 
N/A 
HAMAs blocking reagent 
(Mouse IgG) 
57224 Jackson immune 
Research 
1µg/ul N/A 
Tau lyophilized standard 
(10µl) 
0118-01 AJ Roboscreen N/A N/A 
N/A – not application 
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2.4. Methods 
2.4.1. Blood sampling  
Blood samples (from human and Mesocricetus auratus) was collected into heparin (for 
plasma) or heparin free (for serum) test tube (table 4) and centrifuge using Heraeus 
multifuge X1R (table 4) at 2500xg for 10minutes at 20oC to obtain plasma or serum 
respectively. The obtained plasma or serum was stored at -80oC until needed.  
 
2.4.2. SH-SY5Y Cell culture processing 
As a positive control, SH-SY5Y cells were obtained from the cell line bank of PFI and 
processed as described elsewhere [Park et al., 2015] but with major modification. Briefly, 
SH-SY5Y cells were cultured in Dulbecco's Modified Eagles Medium (DMEM) Ham´s F-12, 
1:1 (table 5) which has been supplemented to 10% fetal calf serum (FCS), 1x non-essential 
amino acid and 1x Gentamycin (table 5). Subsequently, SH-SY5Y cells (4.9 x 106) were 
seeded in a Greiner bio-one 10cm dish (table 4) containing DMEM until a confluence of at 
least 80% was observed.  
To avoid the potential contaminates from exogenous ECVs in DMEM containing FCS, the 
medium to be used to grow the transfected cells was ultracentrifuge at 100,000 x g for 18 
hours using SORVALL® COMBI PLUS (table 4) with the aim of pelleting any vesicle that 
may be present. The supernatant collected was considered as ECV-free medium. Seeded 
SH-SY5Y cells in ECV-free medium were transfected with cDNA (1µg/µl, self-prepared) for 
human tau protein. Prior to the transfection, the cDNA was re-suspended in a mixture of 
JetPEI and Opti-MEM® (table 5). The transfected cells were incubated at 37oC with CO2 for 
48hours. The cell supernatant (40ml) containing the released ECVs was harvested and 
pre-cleaned. Cell lysate from the SH-SY5Y cell as well as a 48-hour seeded neuro-2A cells 
lysate were included as positive and negative controls respectively where necessary.  
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2.4.3. Isolation of ECVs 
2.4.3.1. Pre-cleaning of serum, plasma and cultured supernatant  
To get rid of dead cells, cells and other contaminants samples were subjected to 
increasing sequential centrifugation, starting with 300xg for 10 minutes, followed by 
3000xg for 10 minutes and then finally 10,000xg for 30 minutes. All the centrifugations 
were performed using SIGMA laboratory centrifuge (table 4) at a temperature of 4oC.  
 
2.4.3.2. Precipitation of ECVs  
The procedure for exosome isolation from serum or plasma outlined in the HansaBioMed, 
EXO-Prep (One step Exosome isolation Reagent) datasheet was followed. Regarding the 
suggested volumes, 100µl of plasma and 250µl of serum were used. All reagents used for 
this experiment were all enclosed in the obtained HansaBioMed EXO-Prep kit.  
 
2.4.3.3. Pelleting of ECVs 
To pellet ECVs, serum or plasma was aliquoted into a 13 x 51mm SETON open-top 
centrifuge tube (table 4) and the tube was filled to ¾ with 10% Dulbecco’s phosphate 
buffered saline (PBS). The PBS was added to the serum to reduce viscosity and to prevent 
possible collapse of the tube during ultracentrifugation. The ECVs were pelleted and 
washed at 100,000xg for 2 hours at a temperature of 4oC using micro-ultracentrifuge 
(table 4). The pelleted ECVs were resuspended in 1/10th the starting material of PBS. 
 
2.4.3.4. Density gradient ultracentrifugation and fractionation 
To prepare density gradient, the method described by Lane and colleagues [Lane et al., 
2017] was modified and adopted. Here, iodixanol (VISIPAQUETM 320) or sucrose density 
gradient was prepared. A discontinuous iodixanol (VISIPAQUETM 320) gradient with 
concentrations 40% (w/v), 30% (w/v), 20% (w/v), 10% (w/v) and 5% (w/v) was self-
prepared from a stock solution (62.5% w/v) of VISIPAQUETM 320 (table 5) and PBS. 
Similarly, a discontinuous sucrose gradient with 5 different concentrations; 2.4M, 2.0M, 
1.5M, 1.0M and 0.5M was also self-prepared from a sucrose stock solution (2.5M) and 
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PBS. The gradients were formed by overlaying 920µl of each of the iodixanol or sucrose 
concentrations in 13 x 51mm SETON open-top centrifuge tube polyclearTM (table 4) 
starting with the highest concentration at the bottom and sequentially to the lowest at 
the top. Pelleted ECVs were carefully overlaid on top of the lowest concentration and 
allow to sediment into the iodixanol or sucrose by ultracentrifugation at a speed of 
100,000xg for 18 hours at 4oC using micro-ultracentrifuge (table 4). Twenty-four (24) 
fractions each approximately 195µl were collected in decreasing order of concentration 
with a self-assembled fractionator (Figure 2-1) into a sterile round bottom 96-well Greiner 
bio-one plate (table 4). The procedure is summarised in the flow chart of figure 2-1.  
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Figure 2-1: A flow chart showing the sequential process as well the fractionator setup for 
the purification of ECVs. 
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2.4.3.5. Bead-assisted technique 
Flow cytometric analysis can be the simplest and most sensitive technique for detecting 
ECVs [Zhu et al., 2014]. But, as the modern flow cytometers were designed to study cells, 
particles with size less than that of cells are difficult to be a resolved by the scattering 
light using the conventional flow cytometers [Steen, 2004; van der Pol et al., 2012; 
Morales-Kastresana; Jones, 2017]. The basic principle in flow cytometer is its ability to 
measure scattered light in either forward or sideward direction at an angle following a 
passage of a cell or particle through a laser beam. Typically, the limit of ungated 
scattering light in the commercial flow cytometers is around 300nm – 500nm [Steen, 
2004]. And as ECVs have varied sizes, vesicles less than 300nm has the tendency of not 
scattering forward light and this may affect the acquisition of forward scattering light and 
lead to interpretation issues. To overcome this challenge, a suitable bead can be coated 
with the ECVs. Coupling of ECVs onto beads increases their size and makes them 
discernible enough to be reliably resolved in the flow cytometer [Morales-Kastresana; 
Jones, 2017]. In addition to the fact that the beads increase the size of the ECVs, it also 
concentrates these vesicles and improves the outcome of the forward scattering light. 
Based on this background information, the bead-assisted (specific) technique for the 
isolation of ECVs was exploited. In this technique, beads interact with specific antibodies 
to generate high affinity binding, bead-antibody complex. The complex is then used to 
capture the ECVs via specific antigens on the vesicles. 
The bead-assisted techniques for isolating ECVs or ndECVs as described [Oksvold et al., 
2015; Park et al., 2015; Pedersen et al., 2017] was modified for this study. Briefly, 
Streptavidin MagneSphereR beads (table 5) were washed and resuspended in 0.1% BSA 
sample buffer in an Eppendorf tube. Into the washed magnetic beads, the primary 
antibody, CD63Biotin or CD171Biotin (table 3) was added and incubated for 30 minutes at 
room temperature on a rotating roller (table 4). Unbound antibodies were washed off by 
placing the tube on a magnetic stand and pipetting off the clear supernatant. The 
remaining magnetic bead-antibody complex was resuspended in 0.1% BSA sample buffer 
and pelleted ECVs added. The entire mixture was incubated overnight (18hours) at 4oC 
with gentle agitation. Either the captured ECVs on the bead or the uncaptured ECVs in the 
suspension were collected separately and named as ECVs or non-ndECVs respectively; or 
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ndECVs (CD171+) or non-ndECVs (CD171-) respectively. To prevent potential degradation 
of proteins by proteases, protease inhibitor cocktail (table 5) was added to each sample 
that was to undergo further downstream analysis.  
An ideal volume of beads for a given test was determined to be 5µl (2.36x105particles/µl). 
This suitable volume was obtained after several test-trials (not shown here) and it was 
also found to be suitable for measuring by flow cytometer. 
 
2.4.4. Detection, characterization and quantification of ECVs and the cargo tau protein 
2.4.4.1. Western blot analysis 
The Laemmli’s principle [Laemmli, 1970] of using sodium dodecyl sulphate (SDS) as 
detergent for electrophoretic separation of small proteins in polyacrylamide gel (PAG) 
was adopted in this study as well as the procedure for performing western blot outlined 
earlier [Mahmood; Yang, 2012] was modified and adopted. Here, into PCR tubes (table 4), 
3 parts of the isolated ECVs was added to 1 part of 4X SDS sample buffer (table 6). The 
mixture was heated at 95oC for 5 minutes using master cycler gradient (table 4) to heat 
denatures the ECVs. Equal volumes (20µl) of the ECVs lysate were loaded into each lane 
of a self-prepared 10% SDS-PAG (table 6) and electrophoresed at a constant 170V for 
about an hour in SDS running buffer (table 6). The separated proteins were subsequently 
electro-transferred at 26V onto polyvinylidene difluoride (PVDF) membrane (Table 4) in 
Bjerrum Schafer- Nielsen (B/S-N) transfer buffer (table 6) overnight at 4oC using electro-
blotter tank device (table 4). The membrane was washed in Tris-buffered saline (TBS) and 
blocked in 1% bovine serum albumin (BSA) fraction V (table 5) in TBS containing 0.01% 
Tween® 20 (table 5) for 1 hour at room temperature. The PVDF membrane was stained 
with primary antibody (table 2) and incubated overnight at 4oC with gentle shaking. The 
PVDF membrane was washed in TBS containing 0.01% Tween® 20 to remove any unbound 
primary antibody and was subsequently stained with the detection (secondary) antibody 
(table 2) for 2 hours at room temperature. The membrane was developed with enhanced 
chemiluminescent (ECL) reagents, Lumigen ECL utra solution A and B (table 5) and 
visualized using “Dnr Bio-Imaging System” (table 4). 
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2.4.4.2. Determination of the density of the isolated ECVs 
To determine the buoyant density of the isolated ECVs, the densitometry technique 
described by Théry and colleagues [Théry et al., 2006] was modified and adopted. Here, 
the refractive indices of the entire fractionated fractions (1- 24) obtained earlier (2.4.2.4) 
were measured using Abbe-refractometer (Modell G, Jena, Germany). Fractions that 
show positive reaction for the ECVs markers proteins were noted and their respective 
densities determined.  
 
2.4.4.3. Detection of ECVs using flow cytometry technique 
The ECVs were pelleted by ultracentrifugation as described earlier (2.4.3.3). Beads were 
coated with antibodies (table3) directed against ECVs’ generic marker protein CD63 or cell 
type-specific marker protein CD171 as described (2.4.3.5). Coupled beads-antibody 
complex were used to capture and concentrate the pelleted ECVs. The captured ECVs on 
the beads were subsequently detected by a second antibody that has been conjugated 
with the fluorophore, phycoerythrin (PE, table 3). As negative control, 1% BSA in PBS was 
added to immunomagnetic bead instead of isolated ECVs. All dilutions and resuspension 
were made in 1% BSA sample buffer (table 6)  
Data on the detected ECVs was acquired in the flow cytometer, guava easyCyteTM (table 
4) and analyzed using the Flowjo version 10. The qualitative mean intensity of the 
detection antibody is shown by both histogram and bar chart. The entire procedure is 
summarized in figure 2-2. 
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Figure 2-2: A flow chart showing the sequential approach used in the isolation, detection and 
verification of ECVs from serum or plasma using bead-assisted technique. PBS represent 
phosphate buffered saline, 100k represent the 100,000xg, the speed at which ultracentrifugation 
was performed. 
 
2.4.4.4. ECVs’ cargo protein detection using flow cytometry 
The procedure outline in Miltenyi Biotec datasheet (Inside Stain Kit) for “Intracellular 
staining of eukaryotic cells”, specifically, the protocol for solid phase intracellular staining 
for flow cytometric analysis was followed but with slight modification. Briefly, serum 
sample was obtained (2.4.1) from young healthy donor, pre-cleaned (2.4.3.1) and ECVs 
pelleted by ultracentrifugation as described earlier (2.4.3.3). Beads were coupled with 
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antibody directed against ECV generic marker protein CD63 or cell type specific marker 
protein CD171 as described by the bead assisted technique (2.4.3.5). The beads that have 
been coupled to the antibodies were used to capture the pelleted ECVs as described 
earlier (2.4.3.5). Captured ECVs on the beads were resuspended in 50µl of cyto-last buffer 
(table 5). Subsequently, 50µl of Inside Fix (table 5) was added, mixed well and incubated 
at room temperature for 20 minutes. The fixed ECVs on the beads were permeabilised 
and stained with a cocktail containing 4µl of anti HSP70-PE diluted in 36µl (such as 1:9) of 
Inside perm (table 5). Following incubation (10 minutes), the stained cargo in the pellet 
was resuspended in Inside perm (100µl). As a negative control, an irrelevant coupled 
antibody (isotype control) that has been conjugated to the fluorophore, PE was diluted in 
the Inside perm and incubated along with the experiment. Two positive controls were 
included, pelleted ECVs from SH-SY5Y cells suspension and SH-SY5Y cells. Data was 
acquired by the flow cytometer (2.4.4.3). 
 
2.4.4.5. Enzyme linked immunosorbent assay (ELISA) analysis technique 
To make tau protein in the vesicles accessible for ELISA quantification analysis, the 
pelleted ndECVs (CD171+) and non-ndECVs (CD171-) were lysed with 1% Triton-100 (table 
5) as described [Osteikoetxea et al., 2015] was modified and adopted. Briefly, into 1ml 
Eppendorf tube, 45µl of CD171+ or CD171- ECVs were aliquoted into with 5ul of Triton-
100 added and incubated on ice for at least 5 minutes. Subsequently, 450µl of PBS was 
added to reduce the concentration of the Triton solution in the sample. Also, the dilution 
of the lysis buffer was necessary to avoid possible interference with the subsequent ELISA 
analysis. Potential cross reactivity and nonspecific binding sites in the samples were 
blocked with 1µg/µl anti human anti-mouse antibodies (anti-HAMAs) (table 3). Of the 
processed sample, 25µl was aliquoted for the subsequent downstream enzyme linked 
immunosorbent assay (ELISA) analysis.  
A 96 well mircoplate (table 4) was coated with 50µl each of 0.1M carbonate buffer (PH 
9.7) containing 4µg/ul antibody 1G2 (table 3) and incubated overnight (16 hours) on 
gentle a shaker at 4oC. The incubated plate was washed 6 times with 10mM TBS 
containing 0.05% tween 20 (TBS-T20) using ELISA plate washer (table 4). Nonspecific 
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binding sites on the coated antibodies were blocked with 150µl of 1% BSA sample buffer 
(table 6) in TBS-T20 containing 1µg/µl HAMAs for at least 1 hour. The detection antibody-
mix was prepared by diluting one part of antibody 7E5-HRP (3µg/µl, table 3) in 6000 part 
of 0.1M carbonate of PH 9.7 containing 3% BSA and 0.05% Tween 20. Twelve (12) 
multichannel Finnpipette (table 4) was used to aliquot 25ul of the detection antibody mix 
into the 96 well, and 25ul of the prepared human samples (serum, supernatant, CD171+ 
ECVs or CD171- ECVs) were added. Tau lyophilized standard (table 3) was used to prepare 
different concentrations in 1% TBS-T20 containing 0.01µg/µl HAMAs and was used to 
draw the standard curve. A summary of the entire process is presented in figure 2-3. 
 
Figure 2-3: A flow chart summarizing the procedure prior to ELISA and flow cytometry (FC) 
analysis. The PI represent protease inhibitor while the HAMAs represent a blocker of human anti-
mouse antibodies, DC represent differential centrifugation. 
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Two positive controls were included in this experiment to provide as a proof that tau 
protein was measurable in the vesicles. The first being SH-SY5Y cells that have been 
transfected with cDNA for human tau protein (2.4.2). While the second was blood 
samples from Mesocricetus auratus hibernators that were in the torpid state (5 - 10oC). 
For negative control, 1% BSA sample buffer containing 2% protease inhibitor and 1µg/ml 
mouse IgG was included. 
 
2.5. Statistical analysis 
To show whether tau protein was measurable in serum, ndECVs (CD171+) or non-ndECVs 
(CD171-), scatter plot (GraphPad prism 8.1.0) was used to demonstrate the frequency of 
the measured concentration. To compare the means of tau protein concentration serum 
to that of CSF, unpaired student t-test (GraphPad prism 8.1.0) was performed to 
determine the significant difference between them. Subsequently, Pearson correlation 
coefficient (GraphPad prism 8.1.0) was used to determine possible relationship between 
tau protein in the ndECVs or serum and four validated markers of AD (CSF-tau, CSF-ptau, 
CSF-Aß and MMSE). Finally, unpaired t-test was used to evaluate tau protein from the 
serum of hamsters (positive control).  
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3. RESULTS 
 
3.1. Establishment of protocol for the isolation and characterisation of ECVs 
The result is broadly presented into two (2) parts. The first part (3.1) presents series of 
analysis performed with the aim to establish a valid protocol for the isolation and 
characterisation of ECVs. Having established a reproducible protocol for the isolation and 
characterisation of the vesicle, the next part (3.2) is focused on detection and 
quantification of cargo proteins in the isolated ECVs.    
 
3.1.1. Precipitation versus ultracentrifugation techniques of isolating ECVs  
The use of precipitation technique for the isolation of ECVs is common however, majority 
of studies using this technique are often interested in the evaluation of the RNAs content 
of the ECVs [Li et al., 2014; Prendergast et al., 2018; Patel et al., 2019]. Hence possible 
contaminant from protein aggregate was not considered an issue. Since this study was 
focused towards quantification of tau proteins in the ECVs there was the need to identify 
a suitable technique that will not introduce protein contaminates. Therefore, the 
precipitation technique of isolating ECVs was compared to the ultracentrifugation 
technique. 
Here, ECVs that have been isolated by either precipitation (2.4.3.2) or ultracentrifugation 
techniques (2.4.3.3) were verified using western blot analysis (2.4.4.1). Precipitated ECVs’ 
proteins were electro-transferred onto membrane A (Figure 3-1A) while ultracentrifuge 
pelleted ECVs’ proteins onto membrane B (Figure 3-1B), and both membranes stained 
with ECVs’ marker protein HSP70 and detected by anti-mouse immunoglobulins HRP. As 
HSP70 is one of the cytosolic protein markers for ECVs, a positive reaction in any of the 
preparation (precipitation or ultracentrifugation) suggests that the ECVs are present. Also, 
the HSP70 protein has a molecular weight of 70kDa, and therefore a migration to this 
region is suggestive of a positive reaction. From the results shown (Figure 3-1A & 3-1B), 
no obvious positive reaction for HSP70 was detected in the precipitated sample (either 
serum or plasma). On the contrary, an obvious positive reaction for HSP70 was detected 
in the ultracentrifuge sample (plasma and serum). Also, included on the membrane B 
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(Figure 3-1B right) is a serum sample that underwent only pre-cleaned (Pc) process 
(2.4.3.1), and like the precipitation method, ECVs’ marker protein HSP70 was not 
detected. SH-SY5Y cells lysate was included to provide a positive control.  
 
Figure 3-1: Western blot analysis result of HSP70 ECVs.  Precipitated ECVs (membrane A) shows 
no detectable reactivity for HSP70 (70kDa). Membrane B (left, plasma & serum) ultracentrifuge 
ECVs shows detectable reactivity for HSP70 (70kDa). Membrane B (right), pre-cleaned ECVs shows 
no detectable reactivity for HSP70 (70kDa). “Pc” represents pre-cleaned. The arrows point to the 
region where the ECVs’ marker protein, HSP70 reactivity is expected.   
 
 
3.1.2. Purification of ECVs using iodixanol or sucrose density gradient 
Generally, either iodixanol or sucrose density gradient is used to purify ECVs; however, 
this study wanted to identify which of these two is ideal. To achieve this, a serum sample 
that has been pre-cleaned (2.4.3.1) and ECVs pelleted by ultracentrifugation (2.4.3.3). 
Pelleted ECVs were sedimented through either iodixanol or sucrose gradient (2.4.3.4) was 
compared. Sedimented ECVs were subjected to western blot analysis (2.4.4.1). The ECVs’ 
proteins on the membrane were stained with the primary antibody directed against the 
protein HSP70 and detected by a second antibody, anti-mouse immunoglobulins that 
have been conjugated to horseradish peroxidase (HRP). As shown in the result (Figure 3-
2), a positive reactivity at 70kDa as well as sharp bands (fraction 5 – 9) are observed in the 
iodixanol gradient prepared samples compared to that of sucrose gradient preparation. 
Since HSP70 has molecular weight of 70kDa, the observed reactivity at 70kDa region of 
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iodixanol gradient is considered HSP70 containing ECVs. From the result, it is observed 
that purification of ECVs by iodixanol density gradient produce appropriate outcome 
compared to sucrose gradient. Therefore, the iodixanol gradient was used in subsequent 
analysis where purification of ECVs was needed.       
 
Figure 3-2: Western blot analysis of purification of ECVs by iodixanol (left) and sucrose (right) 
density gradient. An obvious positive reactivity for HSP70 (70kDa) is seen in the iodixanol purified 
ECVs (left). The ECVs purified by sucrose gradient (right) could not demonstrate sharp or positive 
reactivity for HSP70 (70kDa). The arrows point to the region where the ECVs’ marker protein 
HSP70 reactivity is expected.  “Frac.” represent fractions. 
 
3.1.3. Demonstration of other marker proteins of ECVs 
Since at least one cytosolic and one transmembrane protein are required to be 
demonstrated in a vesicular structure to be considered as ECVs, this study simultaneously 
verified for the presence HSP70, CD9 and CD63 proteins in the same processed serum. 
These marker proteins were considered because they the abundant tetraspanin (CD9 and 
CD63) or cargo (HSP70) protein of ECVs. Here, serum was obtained from a single donor, 
pre-cleaned (2.4.3.1), pelleted by ultracentrifugation (2.4.3.3), and purified by iodixanol 
gradient (2.4.3.4). The obtained vesicles were subsequently processed by western blot 
technique (2.4.4.1). Electro-transferred ECVs protein on the PVDF membrane were 
stained with primary antibody directed against the tetraspanin protein CD9 (Figure 3-3A), 
CD63 (Figure 3-3B) or the cargo protein HSP70 (Figure 3-3C). For detection, anti CD9, anti 
CD63 and anti HSP70 stained membrane were respectively stained with second 
antibodies, anti-rabbit immunoglobins HRP, anti-goat immunoglobulin HRP and anti-
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mouse immunoglobulins HRP were used to stain the CD9. The molecular weight of the 
protein CD9 is about 25kDa, CD63 is between 35 – 65kDa, and HSP70 is 70kDa. As shown 
in figure 3-3 the isolates showed positive reaction at 25kDa (A), 35 – 65kDa (B), and 
70kDa (C) for ECVs’ protein CD9, CD63, and HSP70 respectively. This suggests that, the 
pelleted and purified vesicles contained ECVs which settle within iodixanol fractions 
numbered 5 – 10. Included in this experiment are SH-SY5Ycell lysate (positive control) and 
neuro-2A cell lysate (negative control) stained with anti-CD63 (D). The smear appearance 
shown in the membrane stained with CD63 is due to glycosylation.   
 
Figure 3-3: Western blot analysis showing 3 marker proteins of ECVs. Membrane A was stained 
with anti-CD9, B anti-CD63, and C HSP70. Obvious positive reactivity is seen at 25kDa (CD9) region 
(A), 65 – 35kDa (CD63) region (B) and 70kDa CD63 region (C), The control (D) was stained with 
anti-CD63. The arrows point to the region where the ECVs’ marker protein reactivity is expected. 
The smear seen in the CD63 stained membrane is due to glycosylation. 
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3.1.4. Analysis of reproducibility 
Having isolated and purified ECVs from a single donor, the study proceeds to find out if 
the procedure could be reproduced. To achieved this, serum samples were obtained from 
3 healthy young donors and process as described earlier (2.4.3.1, 2.4.3.3, & 2.4.3.4). 
Following the fractionation of the iodixanol gradient containing the ECVs, fractions 
numbered 4 to 10 were selected for each donor and subjected to western blot analysis. 
Membrane containing ECVs’ proteins were stained with a primary antibody directed 
against the protein HSP70 and detected by a second antibody, anti-mouse 
immunoglobulins HRP. An obvious positive reactivity was observed consistently in the 
iodixanol fractions 4 to 10 for all the 3 donors (Figure 3-4). While the obtained result 
demonstrates that the samples contained ECVs, it also shows that the procedure used 
was reproducible. Also shown on the membrane (Figure 3-4) an SH-SY5Y cell lysate served 
as positive control. 
 
Figure 3-4: Western blot analysis of ECVs’ marker protein HSP70 in the serum of 3 young healthy 
donors. The ECVs were purified by iodixanol density gradient. An obvious positive reactivity is 
shown in fraction 4 to 10 for all donors. The arrow points to the region where ECVs’ marker 
protein HSP70 reactivity is expected. The ‘F’ represents Fractions. 
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3.1.5. ECVs’ density determination  
Having observed that the procedure for the isolation and verification of ECVs was 
reproduceable, and that, the ECVs constantly settled in the same fractions, the study 
proceeds to determine the densities of these iodixanol fractions. Here, all the refractive 
indices of the 24 fractions (2.4.3.4) were measured and their respective densities plotted 
(Figure 3-5). Since the verified vesicles settled within fraction 4 and 13 which have 
densities 1.196g/ml and 1.079g/ml respectively, the isolated ECVs were assumed to have 
same buoyant density. The recorded density range for the isolated ECVs in this current 
study falls within the previously reported density range of 1.22 g/ml to 1.08 g/ml [Théry 
et al., 2006; Tauro et al., 2012; Muller et al., 2014; Pérez-González et al., 2017]  
 
 
Figure 3-5: A graph showing the density range where ECVs settle in iodixanol gradient. 
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3.1.5.1. Immunomagnetic isolation of ECVs 
To be able to address isolated vesicles to their parental cells, there is the need to adopt a 
strategy that can define a subpopulation of the ECVs. The bead-assisted technique can be 
used to isolate and concentrate ECVs in general or cell type specific ECVs. Before 
attempting to isolate cell type specific ECVs using this strategy, it is important to first use 
the technique to isolate ECVs in general. Therefore, beads were coated with antibodies 
directed against ECVs’ generic marker protein CD63 using the bead-assisted technique 
(2.4.3.5). The CD63-antibody coupled beads were used to capture the pelleted ECVs (from 
2ml serum). The serum was obtained from a young healthy donor (donor 1) and pre-
cleaned (2.4.3.1) before pelleting by ultracentrifugation.  
The captured ECVs on the beads were detected by a second independent antibody 
directed against the tetraspanin CD9. This second antibody (CD9) has been conjugated 
with the fluorophore, phycoerythrin (PE). The tetraspanin proteins, CD9 and CD63 are 
both generic marker proteins of ECVs. Therefore, a positive signal for CD9 suggests a 
successful isolation of ECVs, and as CD63 was used to capture the vesicles, further 
confirms the sensitivity of the isolation process. Data on the detected ECVs was acquired 
by flow cytometry (2.4.4.3). As a negative control, 0.1% BSA in PBS was substituted for 
the ECVs. The flow cytometry verification result for the detected ECVs is shown in figure 
3-6. An increased CD9 reactivity (positive signal) is observed for the pelleted ECV (Figure 
3-6A). The quantitative mean intensity of the measured CD9-PE in the pelleted ECVs is 
higher than that of negative control (Figure 3-6B). As a positive signal is observed for the 
ECVs’ marker protein CD9, further confirms that the isolate also contain CD63 marker 
protein, hence the protocol was considered appropriate for ECVs isolation.  
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Figure 3-6: ECVs verification result. A histogram (A) that shows the marker protein CD9 in pelleted 
serum. The quantitative mean intensity of the detected CD9-PE is shown on the bar chart (B). 
 
 
 
3.1.5.2. Cell type-specific ECVs (ndECVs) using bead-assisted technique 
Having established a valid protocol for the isolation and detection of ECVs in general 
(3.1.5.1), this study subsequently narrowed to isolating cell type-specific vesicle, the 
ndECVs. Here, beads were coated with antibodies directed against the cell type specific 
ECVs’ marker protein CD171 using the bead-assisted technique (2.4.3.5). The CD171 
coupled beads were used to capture ECVs from ultracentrifuge pelleted serum (2ml) 
obtained from young healthy donors (donor 1 & 2) and has been pre-cleaned (2.4.3.1).  
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For detection and analysis of the captured vesicles, a CD9-specific antibody that has 
coupled to a fluorophore, PE was applied. As CD9 is a generic ECV marker protein, a 
positive signal would confirm a successful isolation of ECVs. Whiles the use of a CD171 
specific antibody for capturing, on the other hand, guarantees the specificity of ndECVs. 
Also, since it is known that SH-SY5Y cells release vesicles which are positive for the 
protein marker CD171, ECVs pelleted from the supernatant of these cells were included 
to provide as positive control. As a negative control, 0.1% BSA in PBS was substituted for 
the ECVs. Data on the detected ndECVs was acquired by flow cytometry (2.4.4.3). 
  
As shown in the result (Figure 3-7), an increased CD9 reactivity (positive signal) is 
observed for donor 1 and 2 compared to the negative control (Figure 3-7B). Since CD9 is a 
generic marker protein for ECVs, the observation confirms that the isolation process for 
the ECVs was successful. And, as the ECVs were captured by CD171-specific antibodies, 
the result further provides assurances that the isolates were indeed ndECVs. Besides, the 
SH-SY5Y cells (positive control) also demonstrated positive signal (right shift) for marker 
protein CD9 (Figure 3-7A). The quantitative mean CD9-PE intensity of donor 1 and 2 as 
well as the positive control (SH-SY5Y) are observed to be higher than that of negative 
control sample as shown in the bar chart (Figure 3-7C).  
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Figure 3-7: Verification result for immunomagnetically captured CD171+ that were analysed by 
flow cytometry. ‘A’ and ‘B’ are histogram that showing CD171+ in the pelleted SH-SY5Y 
supernatant (positive control) in donors’ serum (B) respetively.  ‘C’ is a bar chart showing the 
quantitative mean intensity of the CD9-PE (C). ‘‘Neg.’’ represents negative. 
 
 
 
3.1.6. Comparing serum and plasma as ideal starting material 
Next, the study compared serum and plasma to identify which was the ideal starting 
material for the isolation of ndECVs. The basis for this comparison was to find out if one 
has advantage over the other regarding ndECVs isolation. Here, serum (1ml) and plasma 
(1ml) were obtained from a single donor, pre-cleaned (2.4.3.1) and ECVs pelleted by 
ultracentrifugation (2.4.3.3). The ndECVs from both materials (plasma and serum) were 
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immunomagnetically captured with biotinylated CD171 antibody coupled beads as 
described earlier (2.4.3.5). The captured ndECVs were detected by a second antibody 
CD9. Data on the detected ndECVs was acquired by flow cytometry (2.4.4.3). The flow 
cytometry verification result for the captured ndECVs from both serum and plasma is 
shown in figure 3-8. An approximately equal increased CD9 reactivity (positive signal) is 
observed for the ECVs pelleted from either serum or plasma compared to the negative 
control (Figure 3-8A). Similarly, both plasma and serum showed approximately equal 
quantitative mean intensity of CD9-PE compared to the negative control (Figure 3-8B). 
Based on this finding, either plasma or serum is suitable for the isolation of ECVs. 
 
Figure 3-8: Verification result for the immunomagnetically captured ndECVs from plasma and 
serum of the same donor. ‘A’ is a Histogram showing the positive signal (right shift), and a bar 
chart (B) showing the quantitative mean intensity of the detected CD9-PE from both samples.  
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3.1.7. Optimal minimum starting volume of serum 
Having identified serum as equally suitable material for isolation of ndECVs, the study 
next identified the optimal minimum volume of the serum needed to fully saturate the 
applied beads for capturing the vesicles. Here, ndECVs were isolated from 4 different 
volumes (150µl, 250µl, 500µl and 750µl) of serum from a single donor using the 
ultracentrifuge pelleted technique and the beads assisted technique  
 
Figure 3-9: Flow cytometry verification result of ndECVs from four different volumes of serum. 
The CD9-PE intensity of the captured ndECVs is shown by histogram (A) and bar chart (B).  
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Beads coated with CD171 antibodies were used to capture the ndECVs. Captured ECVs on 
the beads were detected by a second independent antibody directed against the 
tetraspanin CD9. Data on the detected ndECVs was acquired by flow cytometry (2.4.4.3). 
From the result above (Figure 3-9), ndECVs could be isolated from 250µl of serum sample. 
In this experiment, the volume (5µl) of the bead used was always kept constant. As a 
negative control, 0.1% BSA in PBS was substituted for the ECVs. 
 
3.1.8. Isolation of ndECVs from ultracentrifuge or pre-cleaned serum 
It is generally recommended that, the capturing of ECVs should be performing in small 
volumes. Therefore, this study tested whether this was necessary as ultracentrifugation 
process consumes time, material and may not be beneficial to the sample. Here, beads 
that have been coupled with CD171 biotinylated antibody were used to capture ndECVs 
from either 0.5ml pre-cleaned (2.4.3.1) or pelleted 50µl ECVs in PBS (original/starting 
serum 0.5ml). For detection and analysis, a second antibody directed against the 
tetraspanin protein CD9 was used. As a negative control, 0.1% BSA in PBS was substituted 
for the ECVs. Data on the detected ndECVs was acquired by flow cytometry (2.4.4.3). 
From the verification result (Figure 3-10), an increased CD9 reactivity (positive signal) is 
observed for the ndECVs marker protein in both the pre-cleaned and pelleted serum 
compare to the negative control (Figure 3-10A). However, the CD9 signal (reactivity) for 
pelleted ECVs was more pronounced than that of the pre-cleaned serum. Quantitatively, 
a higher CD9-PE mean intensity was observed in the pelleted serum compared to the pre-
cleaned serum (Figure 3-10B).  
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Figure 3-10: Isolation of ndECVs from either pre-cleaned serum or ultracentrifuge 
pelleted serum using bead-based technique. A Histogram (A) showing the ndECVs that were 
detected in the pre-cleaned as well as in the pelleted serum. A bar chart (B) showing the 
quantitative mean CD9-PE intensity. Based on the result, ndECVs were detected in both samples 
but pronounced in the pelleted serum 
 
 
 
 
 
3.2. Detection and quantification of ECVs’ cargo proteins, HSP70 and tau 
Having established a reliable and validated platform for isolation and characterization 
ECVs and ndECVs (3.1.1 – 3.1.8), the study next focused on the quantification of tau 
protein in the ECVs.  
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3.2.1. Western blot technique 
This current study was aimed to quantify tau proteins in the ECVs, however, the cargo 
HSP70 was included to provide a guarantee of procedure. The HSP70 is known to be 
abundant in ECVs and has been demonstrated extensively in this study (Figure 4B, Figure 
5, Figure 6C and Figure 7). Therefore, tau protein and HSP70 were evaluated from 
different volumes of serum. Here, two 11ml each and one 80ml serum were obtained 
from a young healthy donor. The sample was pre-cleaned (2.4.3.1), pelleted by 
ultracentrifugation (2.4.3.3) and purified by iodixanol density gradient (2.4.3.4). The 11ml 
and 80ml serum volumes were arbitrary selected. The purified ECVs were subjected to 
western blot analysis. ECVs obtained from one of the 11ml was stained with antibody 
directed against the protein HSP70, while the ECVs obtained from the other 11ml as well 
as the 80ml serum were stained with polyclonal anti-human tau. For detection, a second 
antibody anti-mouse immunoglobins HRP was used for the membrane that was stained 
previously by HSP70 antibody, while antibody anti-rabbit immunoglobins HRP was used 
for the membrane stained with anti-human tau. 
The tau proteins have molecular weight ranging from 65kDa to 35kDa because of their 
different isoform and proteolytical processing, while HSP70 has a molecular weight of 
70kDa. From the result (Figure 3-11), there is no obvious tau protein reactivity in fraction 
5 – 10 of the 11ml serum (Figure 3-11A), however, there is a weak positive reactivity for 
tau protein in fraction 5 – 10 of the 80ml serum (Figure 3-11B). On the other hand, the 
cargo protein HSP70 showed obvious positive reactivity in fraction 5 – 10 (Figure 3-11C). 
Since HSP70 was clearly shown in 11ml serum, the western blot procedure adopted was 
successful; however, due to low levels of tau protein in ECVs, one may require at least 
80ml of serum to demonstrate tau protein using this analysis platform.  
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Figure 3-11: Demonstration of ECVs’ cargo proteins, HSP70 and tau in different volumes of serum. 
Membrane A, 11ml serum stained with anti-tau but shows no obvious positive reactivity below 
70kDa. Membrane B, 80ml stained with anti-tau and showed weak positive reactivity below 
70kDa. Membrane C, 11ml stained with anti-HSP70 and showed obvious positive reactivity at 
70kDa. The arrows point to the region where the ECVs’ cargo protein tau or HSP70 reactivity is 
expected. The ‘Frac.’ represents fraction. 
 
3.2.2. Flow cytometry 
Although tau proteins in ECVs were demonstrated by western blot analysis, at the least a 
serum volume of 80ml was required and this may pose a challenge. Hence, the flow 
cytometry, a well-established fast and a sensitive technique for quantitative and 
multiparametric analysis of particles was exploited to quantify the tau protein in the 
ECVs.  Prior to using the flow cytometry analysis platform to quantify tau protein in the 
ECVs, the technique was first employed to measure HSP70 in the vesicle to provide a 
proof of principle for the procedure.  Here, serum (10ml) was obtained from a young 
healthy donor pre-cleaned (2.4.3.1) and ECVs pelleted by ultracentrifugation (2.4.3.3). 
The pelleted ECVs were captured by beads (2.4.3.5) that has been coupled with an 
antibody directed against the tetraspanin protein CD63.  
The captured ECVs on the beads were fixed and permeabilized as described earlier 
(2.4.4.4). For detection, the permeabilized ECVs were stained with second antibody 
directed against the ECVs’ cargo protein HSP70. The anti HSP70 was couple to a 
fluorophore, PE. Data on the detected ndECVs was acquired by flow cytometry (2.4.4.3). 
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Cultured SH-SY5Y Cells in suspension were used as positive control. As a second positive 
control was ECVs pelleted from the supernatant SH-SY5Y cultured cells was included. For 
negative control, permeabilized ECVs were stained with irrelevant PE coupled antibody 
(isotype control), and the result shown in figure 3-12.  
 
Figure 3-12: Flow cytometry result showing ECVs’ cargo protein, HSP70 analysis. No obvious 
positive signal is seen for HSP70 in the ECVs from the donor serum (A & B) as well as ECVs from 
the SY5Y cells (positive control, C & D). An obvious positive signal is observed HSP70 from SH-SY5Y 
cells (also positive control, E & F). 
 
From the result above (Figure 3-12) no obvious reactivity (positive signal) for HSP70 was 
observed in the ECVs obtained from the donor (Figure 3.12A and 3-12B). Also, the ECVs 
pelleted from the supernatant of the SH-SY5Y cultured cells (positive control) did not 
HSP70-PE
C
10-3 1030 104
1,0K
1,5K
500
0
SY5Y ECVs‘ HSP70
Negative control
D
Neg. control SY5Y ECVs‘ HSP70
M
e
an
 H
SP
70
P
E 
in
te
n
si
ty
0
10
15
5
20
25
E
102100 101 103 104
200
800
400
0
600
Negative control
SY5Y cells‘ HSP70
1000
F
M
e
an
 H
SP
70
-P
E 
in
te
n
si
ty
120
0
40
60
100
20
80
140
Neg.control SY5Y cells‘ HSP70
HSP70-PE
HSP70-PE
102100 101 103 104
200
800
400
0
600
1000
Negative control
Donor ECVs‘ HSP70
A
2
5
6
3
8
M
e
an
 H
SP
70
-P
E 
in
te
n
si
ty
1
0
4
7
B
Neg.control Donor ECVs‘ HSP70
 49 
 
show any obvious reactivity (Figure 3-12C and 3-12D) for HSP70. On the contrary 
procedure was able to stain intracellular HSP70 in the SH-SY5Y cells (Figure 3-12E and 3-
12F). Indeed, as HSP70 was detectable in the SH-SY5Y cells, the established platform was 
considered feasible except that at present it could not demonstrate the cargo protein in 
the ECVs. 
 
3.2.3. ELISA as an alternative approach to quantify of tau protein in ndECVs 
As the detection of cargo proteins in the ECVs using the flow cytometry technique and 
western blot analysis did not show obvious positive reactivity, this study switched to 
using ELISA as an alternative approach to quantify the tau protein in these vesicles. Here, 
serum (1ml) was obtained from 28 clinical participants who have already undergone the 
routine clinical diagnosis for AD. The serum was pre-cleaned (2.4.3.1) and ECVs pelleted 
by ultracentrifugation (2.4.3.3). A volume 50µl each of the pre-cleaned serum was kept as 
pure serum (serum without ultracentrifugation). Pelleted ECVs were resuspended in 
100µl of sample buffer (table 6). Beads that have been coated with CD171 were used to 
capture the ndECVs as described by the bead-assisted technique (2.4.3.5).  
Captured ndECVs were resuspend in 50µl of sample buffer. From the 50µl of the 
resuspended captured ndECVs 5µl was aliquoted to verify for the presence of CD171+ 
vesicles using flow cytometry (2.4.4.3). The remaining 45µl was lysed with Triton 100 to 
expose the tau protein. Protease inhibitor and anti-HAMAs were added to all samples. 
The ELISA technique (2.4.4.5) was used to detect and measure tau protein in ndECVs and 
non-ndECVs as well as free (soluble) floating tau in serum (pre-cleaned serum). As a 
positive control, ndECVs obtained from SH-SY5Y cells that was transfected with cDNA 
(2.4.2) for human tau protein was included. As a negative control sample buffer 1% BSA in 
PBS was included.  
The result for the measurement of the tau protein is shown in figure 3-13. Based on the 
shown result, the ELISA technique could detect and measure tau protein in human serum, 
ndECVs and non-ndECVs. Also, from the result (Figure 3-13) a higher tau protein 
concentration was measured in the pure serum compared to that of the ECVs.   
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Figure 3-13: A scatter plot showing the measured tau protein concentration in serum, ndECVs and 
non-ndECVs. Also shown is the positive and the negative control results. From the graph higher 
tau protein concentration was measured in the pure serum (serum that underwent only pre-
cleaning). As a positive control, SH-SY5Y cells that has been transfected with cDNA for human tau 
protein was used. 
 
 
3.2.3.1. Comparing the mean tau protein measured in serum and in CSF. 
Since tau protein was measured in the serum and the clinically validated CSF tau protein 
measurement for the same participants were available, this study compared the two 
results. To determine the mean difference between the two measurement of tau protein 
(from serum or CSF), unpaired student t-test was performed. A p-value of 0.05 or less will 
imply that there is a significant difference between the two means. However, the study 
observed that, there was no significant difference (p=0.2708) between the means (Figure 
3-14). As the p-value is greater than 0.05, it suggests that there is no significant difference 
between the mean tau protein measured in the serum and that of CSF.  
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Figure 3-14: A graph comparing mean tau protein concentration in serum and CSF. The ‘ns’ 
represent no significance. There is no significant difference between the mean serum tau protein 
concentration and the mean CSF tau protein concentration. 
 
 
 
3.2.3.2. Correlation between serum tau protein and four AD predictive markers 
Since the clinically validated results (CSF tau, CSF p-tau, β-amyloid and MMSE) of 
seventeen (17) participants were available, this study went further to determine a 
possible correlation between any of this clinically validated AD markers and the measured 
serum tau protein. This was necessary because where strong correlation would be 
observed could serve as basis for further evaluation or monitoring. For instance, if serum 
tau protein correlated strongly with CSF tau protein or β-amyloid, then serum tau 
measurement could be evaluated further and if possible, substitute for these validated 
makers.   
Therefore, Pearson correlation analysis was performed and the correlation coefficient (r) 
of serum tau concentration and the AD predictive markers was determined. Generally, r 
value of +1 is considered as strong positive correlation and r value of -1 is a strong 
negative correlation. An r value of zero (0) is considered no correlation. Therefore, in an 
experiment where correlation coefficient is determined, the obtained r value is compared 
to these values (+1 to -1).  In this current study, the r for serum tau protein and CSF tau 
protein was 0.146 (Figure 3-15A), and that of serum tau protein and CSF p-tau was 0.249 
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(Figure 3-15B). Also, the r for serum tau protein and CSF β-amyloid was -0.467 (Figure 3-
15C), while that of serum tau protein and MMSE was -0.187 (Figure 3-15D). 
As none of the correlation coefficient was zero (Figure 3-15), but close to zero there is no 
strong correlation between the serum tau protein concentration and CSF tau, CSF p-tau 
or MMSE. However, of major interest is the trend for a correlation between serum tau 
protein and CSF β-amyloid (Figure 3-15C). The r value between these markers is – 0.467 
(p=0.059). This trend for a negative correlation (r = -0.467, p=0.059) observed 
demonstrates a pattern that may suggest that AD related reduction of Aβ is accompanied 
by a serum tau increase. But since the p-value was higher than 0.05, the correlation 
between the two markers are not significant. The statistical analysis showing the 
correlation coefficient (r) and the p-value are shown in figure 3-15.   
 
Figure 3-15: Correlation of serum tau protein concentration and four predictive markers of AD. 
Serum tau protein concentration is plotted against; CSF tau (A), CSF p-tau (B), CSF β-amyloid (C) 
and MMSE (D). 
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3.2.3.3. Correlation between ndECVs’ tau protein and four AD predictive markers 
Again, as tau protein was measured in serum-based ndECVs, this study next, correlated 
the tau protein in these vesicles to the four (4) clinically validated AD predictive markers 
(CSF tau, CSF p-tau, β-amyloid and MMSE). With the aim of identifying which of these 
validated makers correlate with ndECVs’ tau protein. Therefore, the Pearson correlation 
coefficient (r) between ndECVs’ tau protein and CSF tau, CSF p-tau, Aβ-amyloid or MMSE 
were performed.  From the result (Figure 3-16), the r values of ndECVs’ tau protein 
concentration and CSF tau (Figure 3-16A), CSF p-tau (Figure 3-16B), CSF β amyloid (Figure 
3-16C) or MMSE (Figure 3-16D) are -0.259, -0.200, 0.024 or -0.185 respectively. Like the 
explanation for r given earlier (3.2.3.2) here also, none of the r values was zero but 
considering the closeness to zero there was no strong correlation.  
 
Figure 3-16: Correlation between tau protein in ndECVs against CSF tau (A), CSF p-tau (B), CSF Aβ 
amyloid (C) or MMSE (D). Also shown on the graphs are the correlation coefficient (r) as well as 
the p values. As none of the r values is zero but close to zero, it appears there was no strong 
correlation between ndECVs’ tau and the AD predictive markers. 
Finally, as the established ELISA technique (3.2.3) could quantify tau protein in serum and 
in ECVs of human, the study further attempted quantifying tau protein in hibernating 
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animals that are in the torpid state. The inclusion of these animals was necessary to serve 
as an additional (beside the SH-SY5Y cells) positive control for ECVs’ tau protein 
measurement using the ELISA technique. It is known that torpid state hibernators show 
AD-like tau protein in their brain [Arendt et al., 2003; Härtig et al., 2007], and therefore is 
possible to detect and measure the protein in their blood. A successful measurement of 
tau protein in the ECVs of these animals would further strengthen the claim that the 
protein was measured in the human samples.  
 
Figure 3-17: A bar graph showing mean tau protein concentration in serum (A) and CD171+ECVs 
(B) of M. auratus (either in torpor or euthermic state). Also shown is the significant difference (*) 
between the means.  
 
Here, ten (10) torpid state M. auratus and ten (10) euthermic state M. auratus were used. 
Serum was obtained from each set of the animal and pre-cleaned as described (2.4.3.1). 
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Each pre-cleaned serum was divided into two parts; one part was subjected to 
ultracentrifugation (2.4.3.3) to pellet the ECVs and the other part kept plain as “serum”. 
Tau protein concentration was measured in both the serum and ECVs for each animal.  
Unpaired t-test was used to compare the mean tau protein concentration between the 
torpid state and the euthermic states animals. Regarding tau protein concentration in the 
serum (Figure 3-17A), a mean value of 99.23pg/ml was recorded for the euthermic state 
M. auratus is while the torpor state M. auratus had a mean value of 337.5pg/ml. Also, 
there was a significant difference in the means of these two measurements which is 
shown by an asterisk on the bar (Figure 3-17A).  
Similarly, the mean tau protein concentration in the ECVs of the euthermic state M. 
auratus was 25.74pg/ml while that of the torpid state M. auratus was 36.76pg/ml (Figure 
3-17B). Like the serum, here also there was a significant difference between the two 
means and is shown by an asterisk in figure 3-17B.  
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4. DISCUSSION 
4.1. Basis for considering blood-based markers for the diagnosis of AD 
In AD, altered metabolic pathways and signalling cascades are not localised to the CNS 
alone but include also peripheral tissue [Gasparini et al., 1998; Stieler et al., 2001; Khan; 
Alkon, 2015]. This postulation is supported by several studies [Ray et al., 2007; Rezai-
Zadeh et al., 2009]. An alteration in the signalling transduction processes involving 
protein kinase C, cyclic AMP, calcium homeostasis, phosphoinositide metabolites and ion 
channel permeability has been observed in both the brain and fibroblast of AD patients 
[Favit et al., 1998; Alkon et al., 2007]. Also, an altered glucose consumption, reduced a-
ketoglutarate dehydrogenase, increased lactate production, decreased glutamine 
oxidation and declined cytochrome c oxidase are significant in both fibroblast and the 
platelets of AD patient [Peterson; Goldman, 1986; Sims et al., 1987; Parker; Parks, 1995; 
BLASS et al., 1997]. Moreover, three important enzymes; Erk1, Erk2 and glycogen 
synthase kinase 3β which are involved in tau phosphorylation are all regulated by protein 
kinase C, an enzyme which is not restricted to the CNS alone [Alkon et al., 2007]. Hence, 
the concomitant dysregulation in the signalling transduction machinery of these enzymes 
in both the brain and the peripheral tissue of AD patient suggests that the disease is 
ubiquitous in nature [Khan; Alkon, 2010; Khan; Alkon, 2015].  
In addition to the altered signalling transduction pathways in peripheral tissue, the 
simultaneous impairment of immune function in the CNS as well as peripheral tissue of 
AD patients further suggest that the disease is not limited to the brain alone. In AD, the 
formation of plaques and tangles activate microglia, astrocytes, and induce other immune 
response such as cytokines, complement proteins, proteinase, chemokines and cell 
surface immune molecules in the brain [Bonotis et al., 2008; Rezai-Zadeh et al., 2009; 
Morris et al., 2014b]. The activation of these neuroinflammatory response in the brain of 
AD, and the fact that, T-lymphocytes can cross the BBB [Wekerle et al., 2000], is reflective 
of the observed dysregulation in the peripheral immune cells [Stieler et al., 2001; Morris 
et al., 2014b]. An extensive illustration of CNS and peripheral tissue immune response in 
AD is available elsewhere [Tollefson et al., 1989; Ikeda et al., 1991; Tan et al., 2002; Chen 
et al., 2006; Richartz-Salzburger et al., 2007].  
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In the peripheral blood, a significant decrease in tumour necrotic factor (TNF) and 
lymphocyte in person with severe cognitive impairment compared to heathy cognitive 
control has been observed [Bonotis et al., 2008]. A positive correlation of peripheral 
blood CD4 subpopulation as well as a negative correlation of interleukin-2 with MMSE 
was observed in severe cognitive impaired individuals [Bonotis et al., 2008]. Further, 
peripheral lymphocytes of AD patients showed decreased proliferative markers after 
mitogenic stimulation compared to cognitive normal control [Stieler et al., 2001; Rezai-
Zadeh et al., 2009; Yoon et al., 2010] 
From the above discussion (inflammatory responses and signalling mechanism), it stands 
to reason that AD is likely more systemic, and that peripheral tissue such as blood may 
provide as important source for early diagnostic markers for the disease. Currently, CSF 
tau, CSF p-tau and β amyloid are among the biomarkers used to diagnose AD. Although 
these biochemical measurements are the gold standard in clinical use, it can also be 
influenced by circadian rhythm [Kang et al., 2009].  Besides, the lumbar puncture 
sampling technique for CSF is invasive and not useful for marker screening, and only 
detects AD in its advance stage [Nagasaka et al., 2005; Khan; Alkon, 2015].  
 
4.2. Basis for targeting tau protein in peripheral blood 
Although neuritic plaques and NFT are the typical features of AD, abnormal deposition of 
plaque (β-amyloid) have been observed in cognitive healthy individuals [Davis et al., 1999; 
Price et al., 2009; Kang et al., 2009; Morris et al., 2014a]. This raises further question 
about the specificity and the sensitivity of the diagnostic value of β-amyloid.  
Again, unlike plaques, the degree of NFT deposition in the brain correlates positively to 
the severity of clinical symptoms of neuronal dysfunction [Holzer et al., 1994; Brion, 1998; 
Hampel et al., 2010]. It has been demonstrated extensively that, the accumulation of NFT 
in the brain follows a hierarchical pattern beginning from the neurons in the trans-
entorhinal region [Hyman et al., 1987; Braak; Braak, 1991; Gómez-Isla et al., 1996], then, 
over years spread across the limbic, and then finally to the isocortical associated areas 
[Braak; Braak, 1991]. This centrifugal spreading pattern of NFT in the brain is consistent 
with the progressive nature of AD symptoms which also begin with anterograde amnesia, 
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speech impairment, mood imbalance and finally lost of executive function [Hyman et al., 
1987; Hyman; Trojanowski, 1997; Calignon et al., 2012]. And since abnormal 
hyperphosphorylated tau protein is the major component of NFT, evaluation of the 
protein in peripheral blood could yield more reliable marker for monitoring AD 
progression [Hampel et al., 2010; Wren et al., 2018]. 
 
4.3. Potential role of ndECVs in the transportation of tau protein  
In recent times, the evaluation of blood-based tau protein as reliable marker for 
predicting AD is on the rise [Fiandaca et al., 2015; Abner et al., 2016; Winston et al., 2016; 
Guix et al., 2018]. The rationale for considering a possible diagnostic role of blood-based 
tau protein is rooted on several logical assumptions. Beginning from the fact that, as tau 
protein becomes hyperphosphorylated, it detaches from the microtubules and relocates 
into the somatodendritic compartment, further phosphorylation and aggregation makes 
it more rigid, insoluble and neurotoxic. The insulted neuron, to overcome the stress from 
this intracellularly accumulated tau deposit, will attempt to expel deposition in a secluded 
manner. And ndECVs has been suggested as the potential culprit that provides a medium 
for the transportation of this abnormal folded tau protein [Kanninen et al., 2016].  
Again, the ability for both ndECVs and tau protein to enter recipient cell via a similar 
mechanistic pathway (endocytosis) further suggest that, ndECVs and tau protein are 
closely linked [Frühbeis et al., 2012]. Also, the sequential spreading pattern (trans-
entorhinal, limbic and to the cortices) of NFT in the brain can be executed by a well-
structured and unrestricted medium such as ndECVs. The ndECVs and its contents, tau 
protein can cross the blood brain barrier into CSF [Süssmuth et al., 2001; Lakhal; Wood, 
2011; Kanninen et al., 2016]. And, on daily basis, about 500µl of CSF is absorbed into 
peripheral blood stream, so ndECVs containing tau protein may use this intermediary 
(CSF) to transverse into peripheral blood [Weinstein; Seshadri, 2014]. In healthy state, 
approximately 2000 trillion ECVs are available [Kalluri, 2016], however, in pathological 
state such as cancers and neurodegenerative conditions, this number is actually change 
[Melo et al., 2015; Kalluri, 2016; Soria et al., 2017]. The quantities of ECVs increase 
proportionally in neurodegeneration [Soria et al., 2017]; hence, the same can be true for 
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ndECVs and its cargo, tau protein in same pathology. Since, ECVs possess signatures of 
their parenting cells, and tau protein is primarily found in the neuron, blood-based 
ndECVs and its cargo, tau may provide useful information that reflects the state of brain 
neuron.  
Based on this background information, this study first aimed at establishing a valid 
protocol to isolate ndECVs and then evaluate the tau protein content within these 
vesicles. 
 
4.4. Establishment of protocol for isolation and characterisation of ECVs 
Since AD is not localised and the disease occurs several years before the onset of clinical 
symptoms, quantification of tau protein in peripheral blood can be used to monitor at-
high-risk individuals. And as mounting evidence suggests that ECVs may be involve in the 
transmission of AD-like tau proteins from the CNS to peripheral blood, further makes the 
evaluation of the protein in the peripheral blood attractive. Blood sampling technique is 
less invasive, does not require sophisticated tools and it involves less time. 
To accept blood based ECVs in clinical settings as a potential source of AD diagnostic 
markers (such as tau protein), the isolation strategy of the vesicle should be efficient and 
reliable. This is because several cells release ECVs into blood, and therefore a method that 
can distinctively define a specific population would be helpful for downstream analysis. A 
plethora of studies have reported on several protocols for isolating ECVs, however there 
are some experimental concerns or issues that still needs to be clarified. For instance, 
whether a protocol designed for cell cultured suspension may be applicable for human 
serum, plasma or urine. It is always important to first define the study goal clearly. As this 
current study was aimed at detecting and quantifying tau protein in ndECVs, it first 
modified and compared several existing ECVs isolation methods and established the most 
suitable one.  Discussed below are the various modifications, comparison and the 
established valid protocol for isolating ECVs and specifically ndECVs.  
As baseline knowledge, ECVs are extracellularly located in body fluids. Hence, to avoid the 
possibility of introducing intracellular structures from disrupted cells and tissues, the 
body fluid (plasma or serum) ought to be sampled and processed gently. This is one of the 
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reasons why plasma or serum is progressively centrifuged (pre-cleaned) prior to isolation 
of ECVs. Also, pre-cleaning is performed before isolation of ECVs is to remove dead cells, 
protein aggregates and debris which can potentially trap or contaminate the vesicles. 
Therefore, all samples obtained were first pre-cleaned before using. 
 
4.4.1. Precipitation versus ultracentrifugation 
Ultracentrifugation and precipitation techniques are among the most commonly used 
method for isolating ECVs from serum or plasma, yet both techniques are not applicable 
in clinical diagnostic setup. The precipitation method is simple and requires less time but, 
there are concerns about the potential co-isolation of non-ECVs such as protein 
complexes and lipoproteins by this method [Lötvall et al., 2014]. Since this study wanted 
an optimal method of isolating ECVs for downstream analysis, the precipitation technique 
was compared to the ultracentrifugation method. Surprisingly, ECVs’ marker protein 
HSP70 was not detected after carefully adopting the precipitation technique for both 
serum and plasma sample (Figure 3-1A). The finding in this current study is at variance 
with previous studies where precipitation method was used to detect ECVs in plasma 
[Helwa et al., 2017], in urine [Alvarez, 2014] and condition cell cultured medium (Weng). 
But it is important to note that, different sources of biological materials (such as plasma, 
serum, culture medium) have varied composition, and therefore the same isolation 
technique may not be applicable to all samples. As those previous studies failed to 
describe how polymeric materials and potential protein contaminants were eliminated in 
their precipitation techniques, using this method to isolate ECVs from human serum or 
plasma remains debatable.  
On the contrary, using ultracentrifugation method, ECV’s marker protein HSP70 was 
detected in both plasma and serum sample suggesting that the isolate contained ECVs. 
Pelleting of ECVs by ultracentrifugation technique is a gold standard procedure for the 
isolation of the vesicles [Zarovni et al., 2015; Li et al., 2017]. Therefore, as this current 
study also isolated ECVs by this same technique, arguably suggest that, 
ultracentrifugation is a crucial step in the processing of ECVs. Again, the observation in 
this study is similar with several studies [Zarovni et al., 2015; Lambrecht et al., 2017; An et 
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al., 2018]. While in the precipitation technique pre-cleaning may be optional [Alvarez, 
2014], ultracentrifugation is always performed after pre-cleaning. As the pelleting of ECVs 
by ultracentrifugation proceeds pre-cleaning of the sample (serum or plasma), possible 
contaminants might have been removed. Furthermore, ultracentrifugation may be a 
necessary step to concentrate the sparsely distributed vesicles. Finally, isolation of ECVs 
by ultracentrifugation appears more likely to yield suitable vesicles for downstream 
analysis.  
To further ascertain if indeed pelleting of ECVs by ultracentrifugation was a major 
requirement, this study attempted to isolate ECVs from serum that has only undergone 
pre-cleaned stage (Figure 3-1B right). But from the western blot verification result, ECVs 
were not detected in the pre-cleaned serum compared to the pelleted serum or plasma 
(Figure 3-1B left). Several reasons could be attributed to this observation. That, in serum, 
ECVs are sparsely distributed and therefore the aliquoted volume for western blot 
analysis did not contain much ECVs, or the amount of the vesicles contained in the 
aliquoted serum was below the detection limit by the western blot technique.  Another 
possible reason is that, the ECVs might have been highly contaminated or trapped in 
other protein aggregates. And that pre-enrichment process by ultracentrifugation at 
100,000xg was necessary to concentrate the ECVs prior to western blot analysis. Again, 
the dilution of the pre-cleaned serum with PBS (2.4.3.3) prior to ultracentrifugation might 
have contributed to reducing the viscosity of the serum and increased the centrifugal 
force on the circulating ECVs and promoting pelleting. Finally, the washing of the pelleted 
ECVs after the first ultracentrifugation might have contributed to removing additional 
contaminants.    
 
4.4.2. Purification of ECVs by density gradient technique 
Although, pelleting by ultracentrifugation was useful to concentrate the ECVs, another 
concern that existed was that, aggregated proteins and large microvesicles could co-
sediment with pelleted vesicles [Tauro et al., 2012] which can invariably compromise the 
purity of the isolated ECVs. Hence to avoid such potential contaminant, the differences in 
the flotation densities of ECVs and the other potential were exploited. To do this, ECVs 
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were purified by either iodixanol or sucrose gradient and the outcome compared. From 
the result (Figure 3-2), purification of ECVs by sucrose gradient showed unsatisfactory 
outcome. Possible reason for this observation may be attributed to the fact that, sucrose 
gradient is unable to properly discriminate ECVs from other larger protein aggregates or 
contaminants. This is possible because, a previous study has also observed that sucrose 
gradient did not sufficiently separate ECVs from non-ECVs [Cantin et al., 2008]. Since the 
formation of ECVs (exosomes and ectosomes) is defined by two pathways, purification 
technique ought to be carefully selected to avoid compounding the existing challenges. 
Thus, a suitable technique that can efficiently separate a ECVs population at a given time 
is preferred.   
Contrary to the sucrose gradient, iodixanol gradient showed an efficient separable result 
(Figure 3-2) like previously reported [Cantin et al., 2008; Tauro et al., 2012]. While sucrose 
gradient has been used elsewhere [Raposo et al., 1996] to separate “so-called” vesicles, it 
is important to again recognised the source of the sample (such as blood, CSF, urine or 
conditioned cell culture medium) as different samples may have varied components. This 
study identified iodixanol gradient as suitable medium that can efficiently purify ECVs 
from either serum or plasma for downstream analysis. Again, though there are two types 
(continuous and discontinuous) of preparing the iodixanol gradient, this study found no 
difference between the two (data not shown). Therefore, the discontinuous method of 
preparing the iodixanol gradient was adopted for the purpose of convenience.  
Next, as it is generally recommended that at least one membrane and one cytosolic 
marker protein for ECVs should be identified in a preparation in order to enable the usage 
of the term “ECVs” [Kanninen et al., 2016], this study went further to verify for additional 
markers in the isolate. The tetraspanin proteins, CD9 and CD63 as well as the cargo 
protein HSP70 were verified from an isolate simultaneously. These proteins were 
exclusively selected because they are abundantly found on or in ECVs and therefore 
demonstration them confirms the presence of the vesicles. Interestingly, within the same 
iodixanol fractions, the marker proteins CD9, CD63 and HSP70 were detected (Figure 3-3). 
Since these markers are generally used to characterise the vesicles, this study considered 
the isolate as ECVs.  
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Following the verification of ECVs’ marker proteins (CD9, CD63 and HSP70) in the pellet of 
a single donor’s serum, the study proceeds to evaluate the reproducibility of the 
procedure. A reproducible protocol is an important step for subsequent downstream 
analysis. Here, ECVs were verified from three (3) young health donors. Remarkably, ECVs’ 
cargo protein HSP70 showed positive reactivity within the same iodixanol fractions for the 
3 donors (Figure 3-4). This current finding further suggests that the iodixanol is a suitable 
medium for the purification of ECVs.     
In addition to using composition (such as CD9, CD63 or HSP70) to characterise ECVs, the 
vesicles are further classified based on its buoyant density. It is presumed that ECVs will 
sediment into iodixanol gradient until it reaches an equilibrium density and float. The 
density of the iodixanol at which the ECVs float is assumed to be the density of the 
vesicle. Using this principle, this study moved a step further to determine the density of 
the isolates. And from the result (Figure 3-5), the densities of the iodixanol fractions that 
contained the ECVs ranged from 1.079g/ml to 1.196g/ml. This observed density range is 
like that reported previously [Tauro et al., 2012; Muller et al., 2014; Pérez-González et al., 
2017]. 
Based on the recorded density range as well as the verified protein markers (CD9, CD63 
and HSP70), the study assumed that, ECVs were successfully isolated, purified and 
verified by ultracentrifugation, iodixanol gradient and western blot techniques 
respectively.  
 
4.4.3. Detection of ECVs’ cargo protein using western blot technique  
Following the successful isolation of ECVs by the establishment of protocol, the study 
next, demonstrates the cargo proteins in the vesicles using western blot as an initial 
platform. Tau protein was the focus however; HSP70 was included as additional cargo 
protein to further confirm the source of the targeted protein. Thus, qualitatively, the 
detection of HSP70 in the isolate will provide as a proof that ECVs were present. Also, 
quantitatively the volume of serum from which HSP70 could be detected, will be 
suggestive for the volume from which tau protein can be demonstrated.  
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As shown by the western blot analysis (Figure 3-11), using 11ml serum, tau protein was 
not obviously detected (Figure 3-11A), while the protein was weakly detected in the 80ml 
serum (Figure 3-11B). Since a weak positive reaction was observed for tau protein in the 
80ml serum, it suggests that to efficiently demonstrate tau protein by western blot at 
least a volume of 80ml would be required. But this will be challenging, as obtaining 80ml 
serum will require sampling of at least 240ml whole blood, a quantity that cannot be 
practicable for routine diagnosis. Even the 11ml serum will require at least 33ml whole 
blood and this will also be a challenge.  
 
4.4.4. ECVs isolation using the Bead-assisted technique  
Though this study has shown that ECVs contain tau protein using the western blot 
analysis (Figure 3-11), quantification of the protein will require at least 80ml serum, 
several days for sample processing and the detected protein could not be addressed to it 
origin. Hence, this study aimed at another method that could quantify cargo proteins 
from specific ECVs (ndECVs) in considerably reduced time and more importantly require 
less starting material.  
Hence, the flow cytometric platform was exploited. Flow cytometry is a simple well-
established sensitive technique for high-throughput qualitative, quantitative or 
multiparametric analysis [Zhu et al., 2014]. Based on light scattering property of flow 
cytometer, information on the morphology, size and shape can be obtained. Also based 
on fluorescence labelling, flow cytometry technique can be used to analyse biochemical 
characteristic (such as antigens) of a cell or particle [Zhu et al., 2014]. However, the 
typical flow cytometers were designed for cells [Zhu et al., 2014] and therefore particles 
below 1µl are generally unable to scatter forward light. The scattering of light in the 
instrument is generally considered an indication that cell or particle is present [van der 
Pol et al., 2012].  
Since the smallest ECVs are about 20nm [Muller et al., 2014], using the typical flow 
cytometer to measure these vesicles directly could pose a challenge, particularly 
regarding forward light scattering. To overcome this drawback, beads were used to 
capture the vesicles before flow cytometry analysis. Coupling ECVs onto beads have the 
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advantage of concentrating several vesicles on a single bead and thereby makes it appear 
large enough to scatter forward light [Morales-Kastresana; Jones, 2017]. Besides, human 
peripheral blood contains a mixture of components including various sizes of ECVs, 
nucleic acid aggregates and subcellular fragment [Muller et al., 2014] which are likely to 
remain in the supernatant following the low-speed (10,000xg) centrifugation (2.4.3.1). 
These aggregates or components can equally sediment along with the ECVs during the 
pelleting by ultracentrifugation process (2.4.3.3) and contaminate the recovered vesicles. 
However, using beads that have been coated with specific antibodies directed against 
ECVs’ marker proteins (CD63 or CD171), one can selectively isolate ECVs which are devoid 
of any contaminants. 
Based on this background information, this study next adopted the bead-assisted strategy 
of isolating ECV for flow cytometry analysis. The technique was first used to isolate 
general ECVs before using it to isolate cell type specific ECVs. This was done to ascertain 
the reliability of using the technique to isolate ndECVs. From the result (Figure 3-6), ECVs 
were isolated by the bead-based method and verified by the flow cytometry, a 
development that was interesting. Earlier, a study has used the bead-assisted technique 
to isolate ECVs except that the material used was cultured cells [Oksvold et al., 2015]. 
Altogether, the bead-based flow cytometry platform was suitable for isolation and 
detection of ECVs. Further, the procedure was rapid, simple and efficient for ECVs 
isolation and analysis  
 
4.4.5. Isolation of cell type specific ECVs (ndECVs) 
As ECVs contain repertoire of signatories from their parental cells, using beads coated 
with antibodies directed against the ndECVs’ marker protein CD171, these cell type 
specific ECVs could be isolated and measured.  This further makes the bead-assisted 
strategy for flow cytometry analysis an attractive technique. Having established a valid 
protocol for isolating ECVs in general (Figure 3-6), the study modified the procedure with 
the aim of capturing ndECVs using CD171 coated beads. Here also, ndECVs were 
successfully isolated from the serum of two independent young healthy donors (Figure 3-
7B).  As neuron derived ECVs are characterized by the marker protein CD171 and cultured 
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human neuroblastoma cell line SH-SY5Y were known to release ECVs which are CD171 
positive [Park et al., 2015], it was included to provide as positive control. Remarkably, the 
technique isolated and measure ndECVs from the positive control (Figure 3-7A) hence, 
the isolation was considered successful. Following this positive finding, the study assumed 
that the bead-assisted technique was suitable for isolating ndECVs for downstream 
analysis. But a major concern that existed was whether to use plasma or serum.  
 
4.4.6. Comparison of plasma and serum as a source of ndECVs 
Is being speculated that, in the process of obtaining serum from blood, ECVs are trapped 
in the clot and this can potentially affect the recovered vesicles [Muller et al., 2014]. 
Likewise, in obtaining plasma from blood, the formation of heparin-ECV complex can also 
deplete the total quantity of the ECVs [Atai et al., 2013]. Considering these important 
concerns, there was the need to compare and identify the most suitable starting material. 
To address these concerns, ndECVs were isolated from both plasma and serum of a single 
donor and compared qualitatively. Interestingly, there was no major difference between 
the qualitative yield ndECVs from both sources (Figure 3-8). Therefore, either plasma or 
serum is just appropriate to be used for the isolation ndECVs. Thus, the choice of serum 
or plasma should be based on the availability. However, to avoid potential interference of 
heparin-ECV complex in plasma which could influence the recovery of ndECVs, this study 
opted to use serum.  
Having isolated of ndECVs from human serum, next, the study focused on identifying the 
ideal minimum volume that could be used as starting material. It is important to identify 
the minimum volume of serum require per flow cytometry test to provide as a guide for 
subsequent analysis. After evaluating different volumes, the study observed that ndECVs 
can be detected and measured from at least 250µl of serum (Figure 3-9). Increasing the 
starting volume is not wrong, however, no significant variation in the measured vesicles 
was observed qualitatively (Figure 3-9) if the used beads are kept constant (5µl). This 
finding is attractive in the sense that not much blood will be required to perform this test 
should it be accepted in clinical settings. 
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Next, the study wanted to find out if the enrichment of ECVs via ultracentrifugation was a 
necessary step or it could be skipped. This could properly save time and uphold the 
integrity of the sample. In address this issue, beads coated with CD171 antibodies were 
used to isolate ndECVs from pelleted serum (2.4.3.3) or pre-cleaned serum (2.4.3.1). It 
was observed that ndECVs can be isolated from either pelleted or pre-cleaned serum 
(Figure 3-10). Although ndECVs could be isolated from pre-cleaned serum, pelleting by 
ultracentrifugation improve the isolation process and this was shown by the pronounced 
positive signal by the pelted vesicles (Figure 3-10). Altogether, using bead-assisted 
technique, ndECVs can be isolated from either pelleted or pre-cleaned serum, and that 
the choice should be based on the intended downstream analysis. 
 
4.5. Detection and quantification of ECVs’ cargo proteins (HSP70 & tau) 
4.5.1. Flow cytometry analysis 
Considering the high-throughput nature of flow cytometry, this study next attempted 
using the technique to detect and quantify tau proteins in ndECVs. But prior to this 
quantifying the tau protein, the study first aimed to quantify HSP70 in the vesicles. The 
demonstration of HSP70 in the vesicles using flow cytometry was due to it abundance in 
ECVs (Figure 3-1B, 3-2, 3-3C, & 3-4). Hence, using HSP70 as an initial target protein to be 
detected is not only suitable but also provides a guarantee for the established protocol. 
To further ensure the robustness of this platform, two positive controls were included. 
The first being SH-SY5Y cells and the second, pelleted ECVs from SH-SY5Y cell suspension. 
As the protein HSP70 is present in SH-SY5Y cells, it was important to include it serve as a 
proof of the principle.  
Surprisingly, the cargo HSP70 was not detected in the ECVs obtained from the young 
healthy donor (Figure 3-12A & 3-12B) as well as ECVs obtained from the supernatant of 
the SH-SY5Y cell (Figure 3-12C & 3-12D). On the contrarily, the protein was detected in 
the cells of SH-SY5Y (Figure 3-12E & 3-12F). The detection of HSP70 in the cells suggests 
that the applied platform is possible except that at present it could not detect HSP70 in 
ECVs. The exact reason for this unexpected result appears complex however, the 
following speculations can be considered. To start with, one of the basic steps in this 
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procedure was fixation of the vesicles and its components by paraformaldehyde. 
Typically, paraformaldehyde functions by inducing cross-linkage among proteins to form 
bridges or mesh. The formation of this bridges help preserve the integrity of the 
components. But because some of the ECVs have a size of about 20nm [Muller et al., 
2014], such a crossing linking characteristic of the fixative could further enhance rigidity. 
Indeed, prior to staining the cargo protein, the ECVs were permeabilised, but due to their 
small sizes and the rigidity confer by the fixative might have rendered the 
permeabilization ineffective. 
Again, another possible reason why the ECVs’ cargo could not be detected in the vesicles 
may be due to the large size of the antibody-fluorophore complex (HSP70-PE). Like the 
fluorophore allophycocyanin (APC) or phycocyanin (PC), the PE also belongs to the family 
phycobilisome which has a diameter of 11nm and a thickness of 6nm all enclosed in a 
central channel of a diameter 4.5nm [FICNER; HUBER, 1993]. Considering this size of the 
PE in addition to the antibody (anti-HSP70) may form a large complex that could not enter 
and stain the cargo in the ECVs. This justification is likely to hold because HSP70 in the SH-
SY5Y cells were stained, possibly because the cells are larger than the vesicles. Based on 
the above discussion, this study suggests that a modification of the antibody and the 
fluorophore to a smaller size could be helpful. 
 
4.5.2. ELISA analysis 
While this study continues to identify the exact reason why the flow cytometry strategy 
was unable to detect the ECVs’ cargo protein (HSP70), there was the need to proceed 
with the evaluation of tau protein in ndECVs from the clinical samples using alternative 
platform. The ELISA method was adopted as alternative approach to detect and quantify 
the protein in the vesicles. The reason for using ELISA was because it is a sensitive 
technique and it has been used extensively to evaluate tau proteins in plasma or serum 
[Vanmechelen et al., 2000; Sparks et al., 2012; Fiandaca et al., 2015; Guix et al., 2018]  
However, in a study by Fiandaca and colleagues, 0.15ml of thromboplastin D was added 
to aid blood clotting. But generally, thromboplastin D is prepared from rabbit brain and 
therefore has the potential of introducing exogenous tau protein into samples [Guix et al., 
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2018]. To avoid the possibility of such exogenous tau protein from thromboplastin D, Guix 
and colleagues substituted thrombin for thromboplastin D [Guix et al., 2018]. But, here 
also, thrombin can truncate or cleave the tau protein [Guo et al., 2017]. Hence neither 
thromboplastin D nor thrombin was added in this current study  
From the ELISA analysis result (Figure 3-13), tau protein was detected and measured in 
the pure serum, ndECVs and non-ndECVs of the clinical samples using the 1G2 antibody 
ELISA assay. Also, tau protein was measured in the ECVs obtained from SH-SY5Y cells 
(positive control). The 1G2 antibody identifies tau proteins that are non-phosphorylated 
at epitope containing Thr175 or Thr181 [Lewczuk et al., 2017]. Since only a small fraction 
of the entire total tau protein is phosphorylated [Lewczuk et al., 2017], an antibody that 
target only phosphorylated site has the tendency to exclude most measurable tau 
proteins. Fortunately, the antibody (1G2) used in this current study was directed towards 
non-phosphorylated epitopes of the tau protein. And therefore, has the advantage of 
measuring most of the available protein as well as quantify the proteins that are not 
phosphorylated at stated epitopes [Lewczuk et al., 2017]. More so, this adopted ELISA 
technique was able measure tau in the ECVs of SH-SY5Y cells (positive control). The SY5Y 
cells has been transfected with cDNA for human tau protein (2.4.2 paragraph 2) and 
therefore the measurement of the protein in the vesicles further guarantees the validity 
of the applied platform. 
Having measured tau protein in ndECVs, the study wanted to identify the possible 
correlation between tau protein in these vesicles and the available predictive markers 
(CSF tau, CSF p-tau & CSF β-amyloid) of AD. Unexpectedly, no obvious correlation existed 
between tau protein in ndECVs and these 3 diagnostic markers of AD (Figure 3-16). 
Possible reason for this finding may be due to the small sample size (28 participants). Of 
the total 28 participants, the assay measured tau protein in the ndECVs of only 7, 
therefore the observed weak correlation is not surprising. As no obvious correlation was 
observed between blood-based ndECVs’ tau protein and any of the validated markers of 
AD, the use of this vesicle-based protein for the diagnosis of AD is currently not 
practicable. Further, due to the observed weak correlation, blood-based ndECVs’ tau 
protein is not feasible to be used as a surrogate to any of the existing AD diagnostic 
markers (CSF tau, CSF p-tau & CSF β-amyloid).   Nevertheless, the measurement of tau 
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protein in ndECVs by this current study is interesting because it further contributes to the 
previous reports that, the protein is measurable in these vesicles [Fiandaca et al., 2015; 
Winston et al., 2016; Guix et al., 2018].  
Like a previous work [Guix et al., 2018], the amount of tau protein measured in the 
ndECVs were less than that measured as free floating in serum. Thus, more tau proteins 
were measured in the pure serum compared to ndECVs or non-ndECVs (Figure 3-13). The 
exact reason for this observation appears complex but the following could be speculated. 
That, following the migration of tau protein in ndECVs from neurons in the brain into 
peripheral blood [Weinstein; Seshadri, 2014], the vesicles then release the tau protein to 
float freely in the tissue. Thus, peripheral blood may serve as the destination for the 
removal of the unneeded tau protein in the brain. And the fact that tau protein was 
detected in the ndECVs arguably suggests that, the vesicle is involved in the 
transportation of the protein into blood.  Another possible reason could be that, tau 
protein encapsulated in migrant ndECVs becomes endocytosed by resident cells in the 
peripheral blood and reduce their quantity.   Moreover, a truncation activity of thrombin 
on tau protein could have resulted in a pseudo-high value since tau protein is highly 
susceptible to thrombin (common in peripheral blood) proteolytic cleavage [Guo et al., 
2017].  
Even though more tau proteins were measured in the serum compared to that of ndECVs, 
there was no strong correlation between the serum tau protein and CSF tau or CSF p-tau 
(Figure 3-15A & 3-15B). However, of major interest was the trend for a correlation 
between serum tau protein and CSF β-amyloid (Figure 15C). The observed trend for a 
negative correlation (-0.467) can be interpreted; as serum tau protein increases CSF β-
amyloid decreases, a pattern that may suggest that AD related reduction of Aβ is 
accompanied by a serum tau increase. 
The former interpretation is more likely because it has resemblance to current clinical 
diagnosis AD (1.3 paragraphs 3). While this finding is exciting, a larger sample size would 
be helpful to substantiate this observation. 
Furthermore, as there are concerns that the neuropsychological tests are influenced by a 
person’s education or race [Crum et al., 1993], the study correlated MMSE to either 
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serum tau or ndECVs’ tau protein. With the aim that where a strong correlation might 
occur, could form basis for consideration or otherwise. The MMSE evaluate a person’s 
orientation to a place and time [McKhann et al., 1984], and is graded on a 30-point scale. 
The following is how MMSE is graded: orientation, 10 points; ability to recall things, 6 
points; ability to concentrate, 5 points; language skill, 8 points; and visuospatial function, 
1-point [Folstein et al., 1975]. A score below 23 points is generally considered abnormal. 
The grading principle of Montreal Cognitive Assessment (MoCA) and the Saint Louis 
University Mental Status (SLUMS) are like that of MMSE except that a score of less than 
25 is abnormal for MoCA [Nasreddine et al., 2005]. Here also, there was no obvious 
correlation between MMSE and serum tau protein (Figure 3-15D) or ndECVs’ tau protein 
(Figure 3-15D). While this study has provided a basis for further study, a larger sample 
size would be required to show the relationship between MMSE and tau protein in the 
ndECVs. In addition to considering a larger sample size in future studies, the use of ultra-
sensitive technique such as single molecule array (simoa) may be considered for the 
measurement of tau protein in the ndECVs. This study was unable to discriminate 
between cancer related ECVs that could also be CD171+ from the neuron derived ECVs 
(CD171+). 
 
4.5.3. Tau protein in the ECVs of hibernating animals 
As discussed earlier for SH-SY5Y cells (4.5.1, paragraph 1), hibernating hamsters 
(Mesocricetus auratus) were also included as a second positive control sample to further 
cornfirm that tau protein in the vesicles were indeed measurable by the ELISA platform. 
The phenotypic lesions of AD have demonstrated in Caenorhabditis elegans, Drosophila 
melanogaster, Xenopus oocytes, mice, European squirrels and hamsters [Lewis et al., 
2000; Arendt et al., 2003; Lee et al., 2005; Härtig et al., 2007]. This study included 
hamsters because hyperphosphorylated tau protein has been demonstrated in the brain 
of torpid state (7oC) hibernators [Arendt et al., 2003]. During reduced body temperature 
(hypothermic state) serine-threonine protein phosphatase activity is inhibited, while 
kinases activities are favoured resulting in the hyperphosphorylation of the tau protein in 
the brain [Planel et al., 2001; Planel et al., 2004; Planel et al., 2007; Whittington et al., 
2011]. As AD is not localised to the brain, one will expect that such AD-like lesion in the 
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hibernators should be accessible in peripheral blood. This was the reason for the inclusion 
of the hamsters.   
Remarkably, tau protein was measured in the serum and ECVs of the hibernating 
hamsters that were in the torpor state (5 – 10oC) as well as euthermic (~37oC) state non-
hibernators (Figure 3-17). Even though tau proteins were measured in these two state 
hamsters, there was a significant difference in the measured means. Thus, more tau 
proteins were measured (both pure serum and ECVs) in the torpid state M. auratus 
compared to the euthermic state ones. This observation was interesting because it 
confirms that tau protein is measurable in peripheral blood.  
In addition to these animals serving as positive control, the study made some 
observations that need to be discussed. In either serum or ECVs, the mean tau protein 
concentration in the torpid state was higher than that of the euthermic state (Figure 3-
17A & 3-17B). The following speculations could be attributed to the observed higher tau 
protein in the torpid hamsters. Hypothermic state induces tau phosphorylation [Planel et 
al., 2004] which may represent a protective mechanism [Arendt et al., 2003], but prolong 
hypothermia may generate excessive hyperphosphorylation of the protein and 
accumulated in the neurons. Further inhibition of protein phosphatase 2A (PP2A) during 
hypothermia [Planel et al., 2001] promote the accumulation of the abnormal protein. In 
addition to the hyperphosphorylated tau protein being toxic to the cells, it is also 
proficient in sequestering other neuronal microtubule associated proteins, MAP1 and 
MAP2 [Alonso et al., 1997]. Due to the permeable state of the BBB during enforced 
hibernation [Baldwin, 1968; Wells, 1972], tau protein may use this channel to exit the 
brain cells into peripheral blood. But to avoid potential insult to neighbouring cells, tau 
protein from the brain may be transported in secluded manner.  The demonstration of 
the tau protein in the ECVs further proofs that these vesicles are the potential culprit in 
the transportation of protein from the brain to the blood. The passage of tau protein 
through BBB is possible during hypothermic state because most of the physiological 
processes such as depolarization, calcium influx and signal transmission are maintained 
[Horowitz; Horwitz, 2019].  
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5. CONCLUSION 
This study is the first to have attempted to measure tau protein in peripheral blood 
ndECVs using flow cytometry technique. While quantification of tau protein by flow 
cytometry platform was a challenge, ELISA technique was used as alternative to measure 
the proteins in the vesicles. Tau protein was measured in the peripheral blood (serum and 
ndECVs) of patients who have already undergone the routine clinical diagnosis for AD. 
However, the study did not observe any strong correlation between tau protein in ndECVs 
and the validated diagnostic markers (CSF tau, CSF p-tau, CSF β-amyloid or MMSE 
evaluation) of AD. Of interest is the trend for a negative correlation (r = -0.467, p=0.059) 
between serum tau protein and CSF β-amyloid, a pattern that may suggest that AD 
related reduction of Aβ is accompanied by a serum tau increase. Peripheral blood is a 
relevant source for tau protein measurement and therefore more studies are needed to 
evaluate the significance of blood serum tau content as a diagnostic biomarker for AD.  
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